1
|
Shuy YK, Santharan S, Chew QH, Lin SK, Ouyang WC, Chen CK, Park SC, Jang OJ, Park JH, Chee KY, Ding KS, Chong J, Zhang L, Li K, Zhu X, Jatchavala C, Pariwatcharakul P, Kallivayalil RA, Grover S, Avasthi A, Ansari M, Maramis MM, Aung PP, Tan CH, Xiang YT, Chong MY, Park YC, Kato TA, Shinfuku N, Baldessarini RJ, Sim K. Pharmacoepidemiology and Clinical Correlates of Lithium Treatment for Bipolar Disorder in Asia. J Clin Psychopharmacol 2024; 44:117-123. [PMID: 38230861 DOI: 10.1097/jcp.0000000000001813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2024]
Abstract
BACKGROUND As clinical practices with lithium salts for patients diagnosed with bipolar disorder (BD) are poorly documented in Asia, we studied the prevalence and clinical correlates of lithium use there to support international comparisons. METHODS We conducted a cross-sectional study of use and dosing of lithium salts for BD patients across 13 Asian sites and evaluated bivariate relationships of lithium treatment with clinical correlates followed by multivariate logistic regression modeling. RESULTS In a total of 2139 BD participants (52.3% women) of mean age 42.4 years, lithium salts were prescribed in 27.3% of cases overall, varying among regions from 3.20% to 59.5%. Associated with lithium treatment were male sex, presence of euthymia or mild depression, and a history of seasonal mood change. Other mood stabilizers usually were given with lithium, often at relatively high doses. Lithium use was associated with newly emerging and dose-dependent risk of tremors as well as risk of hypothyroidism. We found no significant differences in rates of clinical remission or of suicidal behavior if treatment included lithium or not. CONCLUSIONS Study findings clarify current prevalence, dosing, and clinical correlates of lithium treatment for BD in Asia. This information should support clinical decision-making regarding treatment of BD patients and international comparisons of therapeutic practices.
Collapse
Affiliation(s)
- Yao Kang Shuy
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Sanjana Santharan
- Department of Emergency and Crisis Care, Institute of Mental Health, Singapore
| | - Qian Hui Chew
- Research Division, Institute of Mental Health, Singapore
| | | | | | - Chih-Ken Chen
- Chang Gung Memorial Hospital, Keelung Branch, Keelung, Taiwan
| | | | - Ok-Jin Jang
- Department of Psychiatry, Bugok National Hospital, Changnyong, South Korea
| | - Jun Hyuk Park
- Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea
| | - Kok-Yoon Chee
- Department of Psychiatry and Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
| | - Kwong Sen Ding
- Department of Psychiatry, Hospital Bahagia Ulu Kinta, Tanjung Rambutan, Perak Darul Ridzwan, Malasia
| | - Jamaline Chong
- Hospital Permai Johor Bahru, Ministry of Health, Johor Bahru, Malaysia
| | - Ling Zhang
- The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, School of Mental Health, Capital Medical University, Beijing, China
| | - Keqing Li
- Hebei Provincial Mental Health Center, Baoding, Hebei, China
| | - Xiaomin Zhu
- Department of Psychiatry, Suzhou Guangji Hospital, the Affiliated Guangji Hospital of Soochow University, Suzhou, China
| | - Chonnakarn Jatchavala
- Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Pornjira Pariwatcharakul
- Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Roy A Kallivayalil
- Department of Psychiatry, Pushpagiri Institute of Medical Sciences, Tiruvalla, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Moin Ansari
- Department of Psychiatry, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
| | - Margarita M Maramis
- Department of Psychiatry, Dr Soetomo Hospital-Faculty of Medicine, Airlangga University, Surabaya, Indonesia
| | - Paing Phyo Aung
- Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar
| | - Chay Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | | | - Mian-Yoon Chong
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taoyuan City, Taiwan
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, South Korea
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University Fukuoka, Japan
| | - Naotaka Shinfuku
- School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | | | - Kang Sim
- West Region, Institute of Mental Health, Singapore
| |
Collapse
|
2
|
Chen CK, Yang SY, Park SC, Jang OJ, Zhu X, Xiang YT, Ouyang WC, Javed A, Sayeed Khan MN, Grover S, Avasthi A, Kallivayalil RA, Chee KY, Chemi N, Kato TA, Hayakawa K, Pariwatcharakul P, Maramis M, Seneviratne L, Sim K, Lin SK. Corrigendum to "Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study" [Asian J. Psychiatry 85 (2023) 103613]. Asian J Psychiatr 2023; 89:103650. [PMID: 37308390 DOI: 10.1016/j.ajp.2023.103650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- Chih-Ken Chen
- Department of Psychiatry, Keelung Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taiwan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Seon-Cheol Park
- Department of Psychiatry, Hanyang University College of Medicine, Seoul, the Republic of Korea; Department of Psychiatry, Hanyang University Guri Hospital, Guri, the Republic of Korea; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Ok-Jin Jang
- Department of Psychiatry, Bugok National Hospital, Changyeong, the Republic of Korea; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Xiaomin Zhu
- Department of Psychiatry, Suzhou Guangji Hospital, the Affiliated Guangji Hospital of Soochow University, Suzhou, China; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Yu-Tao Xiang
- Unit of Psychiatry, Department of Public Health and Medicinal Administration, Faculty of Health Sciences & Centre for Cognitive and Brain Sciences, University of Macau, Macao Sepcial Administrative Region of China; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Wen-Chen Ouyang
- Department of Geriatric Psychiatry, Jianan Psychiatric Center, Tainan, Taiwan; Department of Psychiatry, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - M Nasar Sayeed Khan
- Department of Psychiatry, Services Hospital, Lahore, Pakistan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Roy Abraham Kallivayalil
- Pushpagiri Institute of Medical Sciences, Tiruvalla, India; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Kok Yoon Chee
- Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Norliza Chemi
- Department of Psychiatry and Mental Health, Hospital Kajang, Selangor, Malaysia; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Kohei Hayakawa
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Pornjira Pariwatcharakul
- Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Margarita Maramis
- Department of Psychiatry, Dr. Soetomo Hospital - Faculty of Medicine, Airlangga University, Surabaya, Indonesia; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Lakmi Seneviratne
- Department of Psychiatry, University of Sri Jayewardenepura, Sri Lanka; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore; Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Shih-Ku Lin
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar; Association for the Improvement of Mental Health Programs, Geneva, Switzerland; Department of Pharmacology, National University of Singapore, Singapore; Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia; School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan; Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.
| |
Collapse
|
3
|
Chen CK, Yang SY, Park SC, Jang OJ, Zhu X, Xiang YT, Ouyang WC, Javed A, Khan MNS, Grover S, Avasthi A, Kallivayalil RA, Chee KY, Chemi N, Kato TA, Hayakawa K, Pariwatcharakul P, Maramis M, Seneviratne L, Sim K, Tang WK, Oo T, Sartorius N, Tan CH, Chong MY, Park YC, Shinfuku N, Lin SK. Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study. Asian J Psychiatr 2023; 85:103613. [PMID: 37163943 DOI: 10.1016/j.ajp.2023.103613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 04/26/2023] [Indexed: 05/12/2023]
Abstract
OBJECTIVE Mood stabilizers are psychotropic drugs mainly used to treat bipolar disorder in the acute phase or for maintenance therapy to prevent relapse. In clinical practice, mood stabilizers are commonly prescribed for conditions other than bipolar disorder. This study investigated the distribution of mood stabilizer prescriptions for different psychiatric diagnoses and studied differences in the drugs, dosage, and plasma concentration in 10 Asian countries including Taiwan, South Korea, Malaysia, China, Thailand, India, Pakistan, Singapore, Indonesia, and Myanmar. METHODS Patients prescribed mood stabilizers (lithium, carbamazepine, valproic acid, or lamotrigine) for a psychiatric condition other than bipolar disorder (codes F31.0-F31.9 in the International Classification of Diseases, 10th Edition, Clinical Modification) were recruited through convenience sampling. A website-based data entry system was used for data collection. RESULTS In total, 1557 psychiatric patients were enrolled. Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (F20-F29, 55.8 %) was the most common diagnosis, followed by non-bipolar mood disorders (F30, F31- F39, 25.3 %), organic mental disorder (F00-F09, 8.8 %), mental retardation (F70-F79, 5.8 %) and anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders (F40-F48, 4.4 %). The most frequently targeted symptoms (>20 %) were irritability (48 %), impulsivity (32.4 %), aggression (29.2 %), anger (20.8 %), and psychosis (24.1 %). Valproic acid was the most frequently used medication. CONCLUSIONS Clinicians typically prescribe mood stabilizers as empirically supported treatment to manage mood symptoms in patients with diagnoses other than bipolar disorders, though there is on official indication for these disorders. The costs and benefits of this add-on symptomatic treatment warrant further investigation.
Collapse
Affiliation(s)
- Chih-Ken Chen
- Department of Psychiatry, Keelung Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taiwan
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan
| | - Seon-Cheol Park
- Department of Psychiatry, Hanyang University College of Medicine, Seoul, the Republic of Korea; Department of Psychiatry, Hanyang University Guri Hospital, Guri, the Republic of Korea
| | - Ok-Jin Jang
- Department of Psychiatry, Bugok National Hospital, Changyeong, the Republic of Korea
| | - Xiaomin Zhu
- Department of Psychiatry, Suzhou Guangji Hospital, the Affiliated Guangji Hospital of Soochow University, Suzhou, China
| | - Yu-Tao Xiang
- Unit of Psychiatry, Department of Public Health and Medicinal Administration, Faculty of Health Sciences & Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR, China
| | - Wen-Chen Ouyang
- Department of Geriatric Psychiatry, Jianan Psychiatric Center, Tainan, Taiwan; Department of Psychiatry, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | | | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Kok Yoon Chee
- Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
| | - Norliza Chemi
- Department of Psychiatry and Mental Health, Hospital Kajang, Selangor, Malaysia
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kohei Hayakawa
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | - Margarita Maramis
- Department of Psychiatry, Dr. Soetomo Hospital - Faculty of Medicine, Airlangga University, Surabaya, Indonesia
| | - Lakmi Seneviratne
- Department of Psychiatry, University of Sri Jayewardenepura, Sri Lanka
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Wai Kwong Tang
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China
| | - Tin Oo
- Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programs, Geneva, Switzerland
| | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia
| | - Yong Chon Park
- Department of Psychiatry, Hanyang University College of Medicine, Seoul, the Republic of Korea
| | - Naotaka Shinfuku
- School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Shih-Ku Lin
- Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.
| |
Collapse
|
4
|
Lin SK, Lane HY. A brief history of clozapine use in Taiwan. Schizophr Res 2023:S0920-9964(23)00224-4. [PMID: 37391310 DOI: 10.1016/j.schres.2023.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 06/13/2023] [Accepted: 06/13/2023] [Indexed: 07/02/2023]
Abstract
Blood concentrations of clozapine in Taiwanese patients appeared approximately 30-50 % higher than that from Caucasian patients, and women possessed a higher blood levels. Fluvoxamine was reported to increase the clozapine levels, reduce clozapine-related weight gain and metabolic disturbances, and improved general psychopathology. Clothiapine, a chemical structure analogue of clozapine, showed potential of benefitting patients who are unsuitable for clozapine treatment in Taiwan. Obsessive/compulsive symptom (OCS) is a common side effect of clozapine. Concentrations of clozapine were remarkably higher in patients with OCS than in those without. In conclusion, clozapine is a widely used in patients with schizophrenia in Taiwan.
Collapse
Affiliation(s)
- Shih-Ku Lin
- Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Hsien-Yuan Lane
- Department of Psychiatry and Brain Disease Research Center, China Medical University Hospital, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung, Taiwan.
| |
Collapse
|
5
|
Deitermann AM, Lin SK, Nugent ST, Raj LK, Beer J, Perz A, Shin TM, Sobanko JF, Etzkorn JR, Miller CJ. Tunneled island pedicle flap reconstruction for upper lateral cutaneous lip defects. J Plast Reconstr Aesthet Surg 2023; 81:119-121. [PMID: 37141785 DOI: 10.1016/j.bjps.2023.04.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/23/2023] [Accepted: 04/18/2023] [Indexed: 05/06/2023]
Abstract
BACKGROUND Esthetic upper lateral cutaneous lip reconstruction preserves the apical triangle, nasolabial fold symmetry, and free margin position. The tunneled island pedicle flap (IPF) is a novel single-stage reconstruction to achieve these goals. OBJECTIVES Describe the technique and patient and surgeon-reported outcomes for the tunneled IPF reconstruction of upper lateral cutaneous lip defects. METHODS Retrospective chart review of consecutive tunneled IPF reconstruction following Mohs micrographic surgery (MMS) at a tertiary care center between 2014 and 2020. Patients rated their scars using the validated Patient Scar Assessment Scale (PSAS), and independent surgeons rated scars using the validated Observer Scar Assessment Scale (OSAS). Descriptive statistics were generated for patient demographics and tumor defect characteristics. RESULTS Twenty upper lateral cutaneous lip defects were repaired with the tunneled IPF. Surgeons rated scars with a composite OSAS score of 11.83 ± 4.29 (mean, SD) [scale of 5 (normal skin) to 50 (worst scar imaginable)] and an overall scar score of 2.81 ± 1.11 [scale of 1 (normal skin) to 10 (worst scar imaginable)]. Patients rated their scars with a composite PSAS score of 10 ± 5.39 [scale of 6 (best possible score) to 60 (worst)] and with an overall score of 2.2 ± 1.78 [scale of 1 (normal skin) and 10 (very different from normal skin)]. One flap was surgically revised for pincushioning, but none experienced necrosis, hematoma, or infection. CONCLUSIONS The tunneled IPF is a single-stage reconstruction for upper lateral cutaneous lip defects with favorable scar ratings by patients and observers.
Collapse
Affiliation(s)
- A M Deitermann
- University of Minnesota Medical School, Minneapolis, MN, United States
| | - S K Lin
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, United States
| | - S T Nugent
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States
| | - L K Raj
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States
| | - J Beer
- Department of Dermatology, Tulane University School of Medicine, New Orleans, LA, United States
| | - A Perz
- Department of Dermatology, Boston University School of Medicine, Boston, MA, United States
| | - T M Shin
- Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
| | - J F Sobanko
- Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
| | - J R Etzkorn
- Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
| | - C J Miller
- Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.
| |
Collapse
|
6
|
Loo LWJ, Chew QH, Lin SK, Yang SY, Ouyang WC, Chen CK, Park SC, Jang OJ, Park JH, Chee KY, Ding KS, Chong J, Zhang L, Li K, Zhu X, Jatchavala C, Pariwatcharakul P, Kallivayalil RA, Grover S, Avasthi A, Ansari M, Maramis MM, Aung PP, Sartorius N, Xiang YT, Tan CH, Chong MY, Park YC, Kato TA, Shinfuku N, Baldessarini RJ, Sim K. Clozapine Use for Bipolar Disorder: An Asian Psychotropic Prescription Patterns Consortium Study. J Clin Psychopharmacol 2023; 43:278-282. [PMID: 37068038 DOI: 10.1097/jcp.0000000000001693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/18/2023]
Abstract
BACKGROUND Pharmacoepidemiological studies of clozapine use to treat bipolar disorder (BD), especially in Asia, are rare, although they can provide insights into associated clinical characteristics and support international comparisons of indications and drug dosing. METHODS We examined the prevalence and clinical correlates of clozapine treatment for BD in 13 Asian countries and regions (China, Hong Kong SAR, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, and Thailand) within an Asian Prescription Patterns Research Consortium. We compared BD patients treated with clozapine or not in initial bivariate comparisons followed by multivariable logistic regression modeling. RESULTS Clozapine was given to 2.13% of BD patients overall, at a mean daily dose of 275 (confidence interval, 267-282) chlorpromazine-equivalent mg/day. Patients receiving clozapine were older, more likely males, hospitalized, currently manic, and given greater numbers of mood-stabilizing and antipsychotic drugs in addition to clozapine. Logistic regression revealed that older age, male sex, current mania, and greater number of other antipsychotics remained significantly associated with clozapine treatment. Clozapine use was not associated with depressed mood, remission of illness, suicidal risk, or electroconvulsive treatment within the previous 12 months. CONCLUSIONS The identified associations of clozapine use with particular clinical features call for vigilance in personalized clinical monitoring so as to optimize clinical outcomes of BD patients and to limit risks of adverse effects of polytherapy.
Collapse
Affiliation(s)
- Lek Wei Javier Loo
- From theLee Kong Chian School of Medicine, Nanyang Technological University
| | - Qian Hui Chew
- Research Division, Institute of Mental Health, Singapore
| | | | - Su-Yu Yang
- Department of Pharmacy, Taipei City Hospital, Taipei
| | | | - Chih-Ken Chen
- Chang Gung Memorial Hospital, Keelung Branch, Keelung
| | | | - Ok-Jin Jang
- Department of Psychiatry, Inje University School of Medicine, Haeundae Paik Hospital, Pusan
| | - Jun Hyuk Park
- Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea
| | - Kok-Yoon Chee
- Department of Psychiatry and Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur
| | - Kwong Sen Ding
- Department of Psychiatry, Hospital Bahagia Ulu Kinta, Tanjung Rambutan, Perak Darul Ridzwan
| | - Jamaline Chong
- Hospital Permai Johor Bahru, Ministry of Health, Johor Bahru, Malaysia
| | - Ling Zhang
- The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, School of Mental Health, Capital Medical University, Beijing
| | - Keqing Li
- Hebei Provincial Mental Health Center, Baoding, Hebei
| | - Xiaomin Zhu
- Department of Psychiatry, Suzhou Guangji Hospital, the Affiliated Guangji Hospital of Soochow University
| | - Chonnakarn Jatchavala
- Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Pornjira Pariwatcharakul
- Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Roy A Kallivayalil
- Department of Psychiatry, Pushpagiri Institute of Medical Sciences, Tiruvalla
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Moin Ansari
- Department of Psychiatry, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
| | - Margarita M Maramis
- Department of Psychiatry, Dr. Soetomo Hospital-Faculty of Medicine, Airlangga University, Surabaya, Indonesia
| | - Paing Phyo Aung
- Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programs, Geneva, Switzerland
| | | | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- Health Management International, Singapore; Regency Specialist Hospital, Johor, Malaysia
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, South Korea
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University
| | - Naotaka Shinfuku
- School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | | | - Kang Sim
- West Region, Institute of Mental Health, Singapore
| |
Collapse
|
7
|
Kubota C, Inada T, Lin SK, Avasthi A, Chee KY, Tanra AJ, Yang SY, Chen LY, Chong MY, Tripathi A, Kallivayalil RA, Grover S, Park SC, Kato TA, Xiang YT, Sim K, Maramis MM, Noor IM, Tan CH, Sartorius N, Shinfuku N. The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study. Hum Psychopharmacol 2023; 38:e2861. [PMID: 36462184 DOI: 10.1002/hup.2861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 10/28/2022] [Accepted: 11/21/2022] [Indexed: 12/05/2022]
Abstract
INTRODUCTION Drug-induced extrapyramidal syndrome (EPS) remains a major problem in clinical psychiatry. This study aimed to examine the factor structure of drug-induced extrapyramidal symptoms observed in patients with schizophrenia and assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). METHODS The participants were 1478 patients with a diagnosis of schizophrenia whose EPS was assessed using the DIEPSS in India, Indonesia, Japan, Malaysia, and Taiwan in the 2016 REAP AP-4 study. The records of the participants were randomly divided into two subgroups: the first for exploratory factor analysis of the eight DIEPSS items, and the second for confirmatory factor analysis. RESULTS The factor analysis identified three factors: F1 (gait and bradykinesia), F2 (muscle rigidity and tremor), and F3 (sialorrhea, akathisia, dystonia, and dyskinesia). CONCLUSION The results suggest that the eight individual items of the DIEPSS could be composed of three different mechanisms: acute parkinsonism observed during action (F1), acute parkinsonism observed at rest (F2), and central dopaminergic mechanisms with pathophysiology other than acute parkinsonism (F3).
Collapse
Affiliation(s)
- Chika Kubota
- Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - Toshiya Inada
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Nagoya, Japan
| | - Shih-Ku Lin
- Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Kok Yoon Chee
- Tunku Abdul Rahman Institute of Neuroscience, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
| | | | - Shu-Yu Yang
- Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Lian-Yu Chen
- Kunming Prevention and Control Center, Taipei City Hospital, Taipei, Taiwan.,Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan.,Department of Forensic Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Mian-Yoon Chong
- Health Management International, Singapore, Singapore.,Regency Specialist Hospital, Johor, Malaysia
| | - Adarsh Tripathi
- Department of Psychiatry, King George's Medical University, Chowk, India
| | - Roy Abraham Kallivayalil
- Department of Psychiatry, Pushpagiri Institute of Medical Sciences and Research Centre, Kerala, Thiruvalla, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Seon-Cheol Park
- Department of Psychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | - Yu-Tao Xiang
- Unit of Psychiatry, Department of Public Health and Medicinal Administration, University of Macau, Macao SAR, China
| | - Kang Sim
- West Region. Institute of Mental Health, Singapore, Singapore
| | | | | | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore, Singapore
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Naotaka Shinfuku
- International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan
| |
Collapse
|
8
|
Huang CY, Lin YF, Chen CR, Lin SK. Post-therapy plasma concentrations of quetiapine in Taiwanese patients. Neuropsychopharmacol Rep 2023; 43:50-56. [PMID: 36647121 PMCID: PMC10009434 DOI: 10.1002/npr2.12303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/19/2022] [Accepted: 10/23/2022] [Indexed: 01/18/2023] Open
Abstract
AIMS Quetiapine is widely used to treat psychiatric disorders such as major depression, generalized anxiety disorder, dysthymic disorder, and insomnia other than schizophrenia and bipolar disorder. This study investigated the diagnostic distribution of quetiapine use in patients in a psychiatric hospital, the doses of quetiapine prescribed, and the plasma concentrations (Cps) of quetiapine and active metabolites. METHODS We enrolled 107 patients who had been prescribed quetiapine for at least 4 weeks. Diagnoses, demographics, and concomitant medications were recorded. Blood sampling was performed in the morning, approximately 12 h after the before-bed dose of quetiapine. RESULTS Diagnoses comprised schizophrenia (n = 25), bipolar disorder (n = 51), major depression (n = 15), dysthymic disorder (n = 9), and others (n = 7). The daily dose (DD) of quetiapine ranged from 25 to 800 (175.9 ± 184.4) mg, with the mean Cp being 105.6 ± 215.3 ng/ml, with a mean Cps/DD ratio of 0.58 ± 0.55 ng/ml/mg. There was a moderate positive linear correlation between the dose and Cps of quetiapine (r = 0.60), and the interpatient variation in Cps/DD ratio was up to 26-fold. CONCLUSION Quetiapine is used in various doses to treat many psychiatric disorders other than psychosis, and it is usually prescribed as a secondary antipsychotic for symptoms such as insomnia or agitation. A wide interpatient variation of the Cps/DD ratio was noticed. Patients of East Asian descent may exhibit a 50% to 100% increase in the Cps/DD ratio for quetiapine compared with patients of Western descent.
Collapse
Affiliation(s)
- Cho-Yin Huang
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Yen-Feng Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Chia-Ru Chen
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.,Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
| |
Collapse
|
9
|
Huang CY, Lin SK. Therapeutic Drug Monitoring of Lurasidone in Patients with Schizophrenia or Bipolar Disorder: A preliminary study. Psychiatry Clin Neurosci 2022; 76:674-675. [PMID: 36057778 DOI: 10.1111/pcn.13466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 08/23/2022] [Accepted: 08/26/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Cho-Yin Huang
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.,Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
| |
Collapse
|
10
|
Li W, Zhang Q, Tang Y, Park SC, Park Y, Yang SY, Chen LY, Lin SK, Najoan E, Kallivayalil RA, Viboonma K, Jamaluddin R, Javed A, Thi Quynh Hoa D, Iida H, Sim K, Swe T, He YL, Ahmed HU, De Alwis A, Chiu HFK, Sartorius N, Tan CH, Chong MY, Shinfuku N, Avasthi A, Grover S, Ungvari GS, Ng CH, Xiang YT. Network analysis of psychiatric symptoms in schizophrenia: Findings from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP). Asian J Psychiatr 2022; 75:103200. [PMID: 35850062 DOI: 10.1016/j.ajp.2022.103200] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 06/22/2022] [Accepted: 07/01/2022] [Indexed: 11/02/2022]
Abstract
AIMS Schizophrenia is a major mental disorder with a wide range of psychiatric symptoms. This study explored the structure of psychiatric symptoms of schizophrenia using network analysis in a large representative Asian sample based on a survey of clinical features and treatment used in schizophrenia patients across 15 countries/territories in Asia. METHODS Data on the demographic characteristics and psychiatric symptoms in schizophrenia patients were extracted from the dataset of the fourth Research on Asia Psychotropic Prescription for Antipsychotics (REAP-AP) project. The presence of the following psychiatric symptoms including delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms, social/occupational dysfunction, verbal aggression, physical aggression, and affective symptoms were analyzed. RESULTS A total of 3681 patients were included. The network analysis revealed that verbal aggression, hallucinations, and social/occupational dysfunction were the most central symptoms, while the connections between social/occupational dysfunction and verbal aggression, and between hallucinations and disorganized speech were the two strongest edges. There were significant gender differences in the network structure based on the network structure invariance test (M=0.74, P = 0.03) and invariant edge strength test. The positive correlation between verbal aggression and hallucinations was significantly stronger in the female network than that in the male network (P = 0.03), while a negative correlation between affective symptoms and negative symptoms was found in the female, but not the male network (P < 0.01). CONCLUSION Central symptoms including verbal aggression, hallucinations, and socio-occupational dysfunction should be addressed in developing targeted treatment strategy for schizophrenia patients.
Collapse
Affiliation(s)
- Wen Li
- Shanghai Key Laboratory of Forensic Medicine, Key Laboratory of Forensic Science, Ministry of Justice, China, Shanghai Forensic Service Platform, Academy of Forensic Science, Shanghai, China
| | - Qinge Zhang
- The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
| | - Yilang Tang
- Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA
| | - Seon-Cheol Park
- Department of Psychiatry, Hanyang University College of Medicine, Seoul, the Republic of Korea
| | - Yongchon Park
- Department of Psychiatry, Hanyang University, Seoul, the Republic of Korea
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan
| | - Lian-Yu Chen
- Kunming Prevention and Control Center, Taipei City Hospital; Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taiwan
| | - Shih-Ku Lin
- Kunming Prevention and Control Center, Taipei City Hospital; Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taiwan; Department of Psychiatry, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
| | | | | | | | - Ruzita Jamaluddin
- Department of Psychiatry & Mental Health, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | | | - Hitoshi Iida
- Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Thiha Swe
- Department of Mental Health, University of Medicine, Magway, Myanmar
| | - Yan-Ling He
- Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
| | | | | | - Helen F K Chiu
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programs, Geneva, Switzerland
| | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung & Chang Gung University School of Medicine, Taoyuan, Taiwan
| | - Naotaka Shinfuku
- International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan
| | - Ajit Avasthi
- Department of Psychiatry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Gabor S Ungvari
- University of Notre Dame Australia, Fremantle, Australia; Division of Psychiatry, Medical School, University of Western Australia, Perth, Australia
| | - Chee H Ng
- Department of Psychiatry, The Melbourne Clinic and St Vincent's Hospital, University of Melbourne, Richmond, Victoria, Australia.
| | - Yu-Tao Xiang
- Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao; Centre for Cognitive and Brain Sciences, University of Macau, Macao; Institute of Advanced Studies in Humanities and Social Sciences, University of Macau, Macao.
| |
Collapse
|
11
|
Lin SK, Yang SY, Park SC, Jang OJ, Zhu X, Xiang YT, Ouyang WC, Javed A, Khan MNS, Grover S, Avasthi A, Kallivayalil RA, Chee KY, Chemi N, Kato TA, Hayakawa K, Pariwatcharakul P, Maramis M, Seneviratne L, Kang S, Tang WK, Oo T, Sartorius N, Tan CH, Chong MY, Park YC, Shinfuku N. Prescription Patterns for Bipolar Disorder in Asian Countries: Findings from Research on Asian Prescription Pattern-Bipolar Disorder. Clin Psychopharmacol Neurosci 2022; 20:61-69. [PMID: 35078949 PMCID: PMC8813322 DOI: 10.9758/cpn.2022.20.1.61] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 12/25/2020] [Accepted: 12/26/2020] [Indexed: 12/29/2022]
Abstract
Objective Pharmacotherapy including mood stabilizers and antipsychotics are frequently used in bipolar disorder (BD); however, the lack of consensus regarding the definition of polypharmacy hinders conducting comparative studies across different settings and countries. Research on Asian Prescription Pattern (REAP) is the largest and the longest lasting international collaborative research in psychiatry in Asia. The objective of REAP BD was to investigate the prescription patterns of psychotropic medications across Asian countries. The rates of polypharmacy and psychotropic drug load were also analyzed. Methods The data collection was web-based. Prescription patterns were categorized as (1) mood stabilizer monotherapy: one mood stabilizer; (2) antipsychotic monotherapy: one antipsychotic; (3) simple polypharmacy: one mood stabilizer and one antipsychotic; and (4) complex polypharmacy: ≥ 2 mood stabilizers or/and antipsychotics. The psychotropic drug load in each patient was calculated using the defined daily dose method. Results Among 2003 patients with BD (52.1% female, 42.4 years) from 12 countries, 1,619 (80.8%) patients received mood stabilizers, 1,644 (82.14%) received antipsychotics, and 424 (21.2%) received antidepressants, with 14.7% mood stabilizer monotherapy, 13.4% antipsychotic monotherapy, 48.9% simple polypharmacy, 20.3% complex polypharmacy, and 2.6% other therapy. The average psychotropic drug load was 2.05 ± 1.40. Results varied widely between countries. Conclusion Over 70% of psychotropic regimens involved polypharmacy, which accords with the high prevalence of polypharmacy in BD under a permissive criterion (2 or more core psychotropic drugs) worldwide. Notably, ≥ 80% of our sample received antipsychotics, which may indicate an increasing trend in antipsychotic use for BD treatment.
Collapse
Affiliation(s)
- Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
- Department of Psychiatry, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan
| | - Seon-Cheol Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Korea
| | - Ok-Jin Jang
- Department of Psychiatry, Bugok National Hospital, Changyeong, Korea
| | - Xiaomin Zhu
- Department of Psychiatry, Suzhou Guangji Hospital, the Affiliated Guangji Hospital of Soochow University, Suzhou, China
| | - Yu-Tao Xiang
- Department of Psychiatry, Beijing Anding Hospital of Capital Medical University, Beijing, China
- Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China
| | - Wen-Chen Ouyang
- Department of Geriatric Psychiatry, Jianan Psychiatric Center, Tainan, Taiwan
- Department of Psychiatry, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | | | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Kok Yoon Chee
- Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
| | - Norliza Chemi
- Department of Psychiatry and Mental Health, Hospital Kajang, Selangor, Malaysia
| | - Takahiro A. Kato
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kohei Hayakawa
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | - Margarita Maramis
- Department of Psychiatry, Dr. Soetomo Hospital - Faculty of Medicine, Airlangga University, Surabaya, Indonesia
| | - Lakmi Seneviratne
- Department of Psychiatry, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
| | - Sim Kang
- Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Wai Kwong Tang
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China
| | - Tin Oo
- Mental Health Hospital, Yangon University of Medicine, Yangon, Myanmar
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programs, Geneva, Switzerland
| | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung & Chang Gung University School of Medicine, Linkou, Taiwan
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Korea
| | - Naotaka Shinfuku
- School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| |
Collapse
|
12
|
de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Anıl Yağcıoğlu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry 2022; 55:e1. [PMID: 35052001 DOI: 10.1055/a-1737-1527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Jose de Leon
- Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA.,Department of Psychiatry, University of Kentucky, Lexington, KY, USA.,Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain.,Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apostol Hospital, University of the Basque Country, Vitoria, Spain
| | - Georgios Schoretsanitis
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.,The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
| | - Robert L Smith
- Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
| | - Espen Molden
- Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.,Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway
| | - Anssi Solismaa
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.,Department of Psychiatry, Tampere University Hospital, Tampere, Finland
| | | | - Miloslav Kopeček
- National Institute of Mental Health, Klecany, Czech Republic.,Department of Psychiatry, Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Patrik Švancer
- National Institute of Mental Health, Klecany, Czech Republic.,Department of Psychiatry, Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Ismael Olmos
- Clinical Pharmacology Unit and Pharmacy Department, Vilardebó Hospital, Administración de Servicios de Salud, Montevideo, Uruguay
| | - Carina Ricciardi
- Clinical Pharmacology Unit and Outpatient Clinic, Vilardebó Hospital, Administración de Servicios de Salud, Montevideo, Uruguay
| | - Celso Iglesias-Garcia
- Universidad de Oviedo. CIBERSAM. INEUROPA. ISPA-FIMBA, Oviedo, Spain.,Hospital Valle del Nalón, Langreo, Spain
| | | | - Edoardo Spina
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - Can-Jun Ruan
- Laboratory of Clinical Psychopharmacology, Beijing Anding Hospital, Capital Medical University, Beijing, China.,The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Chuan-Yue Wang
- The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.,Department of Psychiatry, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Gang Wang
- The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Yi-Lang Tang
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.,Substance Abuse Treatment Program, Atlanta VA Medical Center, Decatur, Georgia, USA
| | - Shih-Ku Lin
- Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.,Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Hsien-Yuan Lane
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.,Department of Psychiatry and Brain Disease Research Center, China Medical University Hospital, Taichung, Taiwan.,Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung, Taiwan
| | - Yong Sik Kim
- Department of Neuropsychiatry, Nowon Eulji Medical Center, Eulji University, School of Medicine, Seoul, Korea
| | - Se Hyun Kim
- Department of Psychiatry, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Anto P Rajkumar
- Department of Psychiatry, Christian Medical College, Vellore, India.,Institute of Mental Health, Jubilee Campus, University of Nottingham, Triumph Road, Nottingham, United Kingdom
| | | | - Helgi Jung-Cook
- Instituto Nacional de Neurología y Neurocirugía, México City, México.,Facultad de Química, Universidad Nacional Autónoma de México (UNAM), México City, México
| | - Trino Baptista
- Department of Physiology, Los Andes University Medical School, Mérida, Venezuela
| | - Christopher Rohde
- Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.,Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Jimmi Nielsen
- Mental Health Centre Glostrup, Copenhagen University Hospital, Copenhagen, Denmark
| | - Hélène Verdoux
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France
| | - Clelia Quiles
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France
| | - Emilio J Sanz
- Department of Physical Medicine and Pharmacology, School of Medicine, Universidad de La Laguna, Canary Islands, Spain.,Hospital Universitario de Canarias, Tenerife, Spain
| | - Carlos De Las Cuevas
- Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, and Instituto Universitario de Neurociencia (IUNE), University of La Laguna, Canary Islands, Spain
| | - Dan Cohen
- Dutch Clozapine Collaboration Group, Castricum, The Netherlands.,FACT-team in Heerhugowaard, Department of Severe Mental Illness, Mental Health Services North-Holland North, The Netherlands
| | - Peter F J Schulte
- Dutch Clozapine Collaboration Group, Castricum, The Netherlands.,Mental Health Team Alkmaar, Mental Health Services Noord-Holland-Noord, Alkmaar, The Netherlands
| | - Aygün Ertuğrul
- Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey
| | | | - Nitin Chopra
- Addictions Division, Centre for Addiction and Mental Health, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | | | - Charles Shelton
- Department of Psychiatry, University of Kentucky, Lexington, KY, USA.,Eastern State Hospital, Lexington, Kentucky, USA
| | - Robert O Cotes
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
| | | | - John M Kane
- The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA.,Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, New York, USA
| | - Saeed Farooq
- School of Medicine, Keele University, Staffordshire, and Midlands Partnership NHS Foundation Trust, Staffordshire, United Kingdom
| | - Chee H Ng
- Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia
| | - John Bilbily
- Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA
| | - Christoph Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Germany
| | - Carlos López-Jaramillo
- Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia.,Programa Trastornos del Ánimo, Hospital Universitario San Vicente Fundación, Medellín, Colombia
| | - Ian McGrane
- Department of Pharmacy Practice, University of Montana, Missoula, USA
| | - Fernando Lana
- Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona, Spain.,Department of Psychiatry, Autonomous University of Barcelona, Spain
| | - Chin B Eap
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland.,Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Switzerland
| | - Manuel Arrojo-Romero
- Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
| | - Flavian Ş Rădulescu
- Center for Drug Sciences, Faculty of Pharmacy, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
| | - Erich Seifritz
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland
| | - Susanna Every-Palmer
- Te Korowai Whāriki Central Regional Forensic Service, Capital and Coast District Health Board, Wellington, New Zealand.,Department of Psychological Medicine, University of Otago, Wellington, New Zealand
| | - Chad A Bousman
- Departments of Medical Genetics, Psychiatry, Physiology & Pharmacology, and Community Health Sciences University of Calgary, Alberta, Canada
| | - Emmanuel Bebawi
- Faculty of Medicine, University of Montreal, Montreal, Canada.,Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montreal, Canada
| | - Rahul Bhattacharya
- East London NHS Foundation Trust, London, United Kingdom.,Honorary Clinical Senior Lecturer, Barts and the London School of Medicine, Queen Mary University of London, United Kingdom
| | - Deanna L Kelly
- Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - Yuji Otsuka
- Department of Psychiatry, Asahi General Hospital, Chiba, Japan
| | - Judit Lazary
- National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary
| | - Rafael Torres
- Department of Psychiatry, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Agustin Yecora
- Secretaría de Salud Mental y Adicciones, Ministerio de Salud de la Provincia de Jujuy, San Salvador de Jujuy, Argentina
| | - Mariano Motuca
- Instituto Vilapriño, Center for Studies, Assistance and Research in Neurosciences, Mendoza, Argentina
| | - Sherry K W Chan
- Department of Psychiatry, LSK Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.,State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR
| | - Monica Zolezzi
- College of Pharmacy, QU Health, Qatar University, Doha, Qatar
| | - Sami Ouanes
- Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar
| | | | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Ric M Procyshyn
- British Columbia Mental Health and Substance Use Research Institute, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| | | | - Oleg O Kirilochev
- Department of Clinical Pharmacology, Astrakhan State Medical University, Astrakhan, Russian Federation
| | - Andrey Soloviev
- Department of Psychiatry and Clinical Psychology, Northern State Medical University, Arkhangelsk, Russia
| | - Konstantinos N Fountoulakis
- 3rd Department of Psychiatry, Division of Neurosciences, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece
| | - Alina Wilkowska
- Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland
| | - Wiesław J Cubała
- Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland
| | - Muhammad Ayub
- Department of Psychiatry, Queens University, Kingston, Canada
| | - Alzira Silva
- Psychiatry Department, Centro Hospitalar Universitário de S. João, Porto, Portugal., Faculdade de Medicina da Universidade do Porto, Porto, Portugal
| | | | - José M Villagrán-Moreno
- Department of Neurosciences, Jerez University Hospital, Andalusian Health Service, University of Cadiz, Jerez, Spain
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain., Spanish Network for Research in Mental Health (CIBERSAM), Sevilla, Spain
| | - Henk Temmingh
- Department of Psychiatry and Mental Health, University of Cape Town, Valkenberg Hospital, Western Cape, Cape Town, South Africa
| | - Eric Decloedt
- Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | | | - Hiroyoshi Takeuchi
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - Masaru Tsukahara
- Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan
| | - Gerhard Gründer
- Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Marina Sagud
- Department of Psychiatry, School of Medicine, University of Zagreb, Zagreb, Croatia.,Department for Psychiatry and Psychological Medicine, University Hospital Center Zagreb, Croatia
| | - Andreja Celofiga
- Department of Psychiatry, University Medical Centre Maribor, Maribor, Slovenia
| | | | - Bruno B Ortiz
- Group of Resistant Schizophrenia (GER), Schizophrenia Program (Proesq), Federal University of Sao Paulo, SP, Brazil
| | - Helio Elkis
- Department and Institute of Psychiatry, University of São Paulo Medical School (FMUSP), Sao Paulo, Brazil
| | - António J Pacheco Palha
- Department and Institute of Psychiatry and Mental Health, Oporto Faculty of Medicine, Oporto, Portugal.,Casa de Salidedo Som Jesus (Psychiatric Hospital), Oporto, Portugal
| | - Adrián LLerena
- INUBE Biosanitary Research Institute of Extremadura. Extremadura University Hospital and Medical School, Badajoz, Spain.,Spanish Network for Research in Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
| | - Emilio Fernandez-Egea
- Cambridge Psychosis Centre, Cambrigeshire and Peterborough NHS Foundation Trust & Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
| | - Dan Siskind
- Metro South Addiction and Mental Health Service, Brisbane, Australia.,Queensland Centre for Mental Health Research and School of Clinical Medicine, University of Queensland, Brisbane, Australia
| | - Abraham Weizman
- Research Unit, Geha Mental Health Center and Molecular Psychiatry Laboratory, Felsenstein Medical Research Center, Tel Aviv, Israel.,Department of Psychiatry Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
| | - Rim Masmoudi
- Psychiatry "A" Department, Hedi Chaker University Hospital, Sfax, Tunisia.,Faculty of Medicine, University of Sfax, Sfax, Tunisia
| | - Shamin Mohd Saffian
- Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | | | - Peter F Buckley
- School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Stephen R Marder
- Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA.,VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA
| | - Leslie Citrome
- New York Medical College, Department of Psychiatry and Behavioral Sciences, Valhalla, NY, USA
| | - Oliver Freudenreich
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA.,Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, New York, USA.,Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany
| | - Daniel J Müller
- Addictions Division, Centre for Addiction and Mental Health, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
13
|
de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, Las Cuevas CD, Cohen D, Schulte PFJ, Ertuğrul A, Yağcıoğlu AEA, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, Berardis DD, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ristic DI, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Saffian SM, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry 2021; 55:73-86. [PMID: 34911124 DOI: 10.1055/a-1625-6388] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas' original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300-600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75-150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175-300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100-200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250-400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150-300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300-600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.
Collapse
Affiliation(s)
- Jose de Leon
- Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA.,Department of Psychiatry, University of Kentucky, Lexington, KY, USA.,Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain.,Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apostol Hospital, University of the Basque Country, Vitoria, Spain
| | - Georgios Schoretsanitis
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.,The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
| | - Robert L Smith
- Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
| | - Espen Molden
- Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.,Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway
| | - Anssi Solismaa
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.,Department of Psychiatry, Tampere University Hospital, Tampere, Finland
| | | | - Miloslav Kopeček
- National Institute of Mental Health, Klecany, Czech Republic.,Department of Psychiatry, Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Patrik Švancer
- National Institute of Mental Health, Klecany, Czech Republic.,Department of Psychiatry, Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Ismael Olmos
- Clinical Pharmacology Unit and Pharmacy Department, Vilardebó Hospital, Administración de Servicios de Salud, Montevideo, Uruguay
| | - Carina Ricciardi
- Clinical Pharmacology Unit and Outpatient Clinic, Vilardebó Hospital, Administración de Servicios de Salud, Montevideo, Uruguay
| | - Celso Iglesias-Garcia
- Universidad de Oviedo. CIBERSAM. INEUROPA. ISPA-FIMBA, Oviedo, Spain.,Hospital Valle del Nalón, Langreo, Spain
| | | | - Edoardo Spina
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - Can-Jun Ruan
- Laboratory of Clinical Psychopharmacology, Beijing Anding Hospital, Capital Medical University, Beijing, China.,The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Chuan-Yue Wang
- The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.,Department of Psychiatry, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Gang Wang
- The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Yi-Lang Tang
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.,Substance Abuse Treatment Program, Atlanta VA Medical Center, Decatur, Georgia, USA
| | - Shih-Ku Lin
- Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.,Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Hsien-Yuan Lane
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.,Department of Psychiatry and Brain Disease Research Center, China Medical University Hospital, Taichung, Taiwan.,Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung, Taiwan
| | - Yong Sik Kim
- Department of Neuropsychiatry, Nowon Eulji Medical Center, Eulji University, School of Medicine, Seoul, Korea
| | - Se Hyun Kim
- Department of Psychiatry, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Anto P Rajkumar
- Department of Psychiatry, Christian Medical College, Vellore, India.,Institute of Mental Health, Jubilee Campus, University of Nottingham, Triumph Road, Nottingham, United Kingdom
| | | | - Helgi Jung-Cook
- Instituto Nacional de Neurología y Neurocirugía, México City, México.,Facultad de Química, Universidad Nacional Autónoma de México (UNAM), México City, México
| | - Trino Baptista
- Department of Physiology, Los Andes University Medical School, Mérida, Venezuela
| | - Christopher Rohde
- Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.,Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Jimmi Nielsen
- Mental Health Centre Glostrup, Copenhagen University Hospital, Copenhagen, Denmark
| | - Hélène Verdoux
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France
| | - Clelia Quiles
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France
| | - Emilio J Sanz
- Department of Physical Medicine and Pharmacology, School of Medicine, Universidad de La Laguna, Canary Islands, Spain.,Hospital Universitario de Canarias, Tenerife, Spain
| | - Carlos De Las Cuevas
- Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, and Instituto Universitario de Neurociencia (IUNE), University of La Laguna, Canary Islands, Spain
| | - Dan Cohen
- Dutch Clozapine Collaboration Group, Castricum, The Netherlands.,FACT-team in Heerhugowaard, Department of Severe Mental Illness, Mental Health Services North-Holland North, The Netherlands
| | - Peter F J Schulte
- Dutch Clozapine Collaboration Group, Castricum, The Netherlands.,Mental Health Team Alkmaar, Mental Health Services Noord-Holland-Noord, Alkmaar, The Netherlands
| | - Aygün Ertuğrul
- Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey
| | | | - Nitin Chopra
- Addictions Division, Centre for Addiction and Mental Health, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | | | - Charles Shelton
- Department of Psychiatry, University of Kentucky, Lexington, KY, USA.,Eastern State Hospital, Lexington, Kentucky, USA
| | - Robert O Cotes
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
| | | | - John M Kane
- The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA.,Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, New York, USA
| | - Saeed Farooq
- School of Medicine, Keele University, Staffordshire, and Midlands Partnership NHS Foundation Trust, Staffordshire, United Kingdom
| | - Chee H Ng
- Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia
| | - John Bilbily
- Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA
| | - Christoph Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Germany
| | - Carlos López-Jaramillo
- Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia.,Programa Trastornos del Ánimo, Hospital Universitario San Vicente Fundación, Medellín, Colombia
| | - Ian McGrane
- Department of Pharmacy Practice, University of Montana, Missoula, USA
| | - Fernando Lana
- Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona, Spain.,Department of Psychiatry, Autonomous University of Barcelona, Spain
| | - Chin B Eap
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland.,Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Switzerland
| | - Manuel Arrojo-Romero
- Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
| | - Flavian Ş Rădulescu
- Center for Drug Sciences, Faculty of Pharmacy, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
| | - Erich Seifritz
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland
| | - Susanna Every-Palmer
- Te Korowai Whāriki Central Regional Forensic Service, Capital and Coast District Health Board, Wellington, New Zealand.,Department of Psychological Medicine, University of Otago, Wellington, New Zealand
| | - Chad A Bousman
- Departments of Medical Genetics, Psychiatry, Physiology & Pharmacology, and Community Health Sciences University of Calgary, Alberta, Canada
| | - Emmanuel Bebawi
- Faculty of Medicine, University of Montreal, Montreal, Canada.,Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montreal, Canada
| | - Rahul Bhattacharya
- East London NHS Foundation Trust, London, United Kingdom.,Honorary Clinical Senior Lecturer, Barts and the London School of Medicine, Queen Mary University of London, United Kingdom
| | - Deanna L Kelly
- Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - Yuji Otsuka
- Department of Psychiatry, Asahi General Hospital, Chiba, Japan
| | - Judit Lazary
- National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary
| | - Rafael Torres
- Department of Psychiatry, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Agustin Yecora
- Secretaría de Salud Mental y Adicciones, Ministerio de Salud de la Provincia de Jujuy, San Salvador de Jujuy, Argentina
| | - Mariano Motuca
- Instituto Vilapriño, Center for Studies, Assistance and Research in Neurosciences, Mendoza, Argentina
| | - Sherry K W Chan
- Department of Psychiatry, LSK Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.,State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR
| | - Monica Zolezzi
- College of Pharmacy, QU Health, Qatar University, Doha, Qatar
| | - Sami Ouanes
- Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar
| | | | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Ric M Procyshyn
- British Columbia Mental Health and Substance Use Research Institute, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| | | | - Oleg O Kirilochev
- Department of Clinical Pharmacology, Astrakhan State Medical University, Astrakhan, Russian Federation
| | - Andrey Soloviev
- Department of Psychiatry and Clinical Psychology, Northern State Medical University, Arkhangelsk, Russia
| | - Konstantinos N Fountoulakis
- 3rd Department of Psychiatry, Division of Neurosciences, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece
| | - Alina Wilkowska
- Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland
| | - Wiesław J Cubała
- Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland
| | - Muhammad Ayub
- Department of Psychiatry, Queens University, Kingston, Canada
| | - Alzira Silva
- Psychiatry Department, Centro Hospitalar Universitário de S. João, Porto, Portugal., Faculdade de Medicina da Universidade do Porto, Porto, Portugal
| | | | - José M Villagrán-Moreno
- Department of Neurosciences, Jerez University Hospital, Andalusian Health Service, University of Cadiz, Jerez, Spain
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain., Spanish Network for Research in Mental Health (CIBERSAM), Sevilla, Spain
| | - Henk Temmingh
- Department of Psychiatry and Mental Health, University of Cape Town, Valkenberg Hospital, Western Cape, Cape Town, South Africa
| | - Eric Decloedt
- Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | | | - Hiroyoshi Takeuchi
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - Masaru Tsukahara
- Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan
| | - Gerhard Gründer
- Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Marina Sagud
- Department of Psychiatry, School of Medicine, University of Zagreb, Zagreb, Croatia.,Department for Psychiatry and Psychological Medicine, University Hospital Center Zagreb, Croatia
| | - Andreja Celofiga
- Department of Psychiatry, University Medical Centre Maribor, Maribor, Slovenia
| | | | - Bruno B Ortiz
- Group of Resistant Schizophrenia (GER), Schizophrenia Program (Proesq), Federal University of Sao Paulo, SP, Brazil
| | - Helio Elkis
- Department and Institute of Psychiatry, University of São Paulo Medical School (FMUSP), Sao Paulo, Brazil
| | - António J Pacheco Palha
- Department and Institute of Psychiatry and Mental Health, Oporto Faculty of Medicine, Oporto, Portugal.,Casa de Salidedo Som Jesus (Psychiatric Hospital), Oporto, Portugal
| | - Adrián LLerena
- INUBE Biosanitary Research Institute of Extremadura. Extremadura University Hospital and Medical School, Badajoz, Spain.,Spanish Network for Research in Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
| | - Emilio Fernandez-Egea
- Cambridge Psychosis Centre, Cambrigeshire and Peterborough NHS Foundation Trust & Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
| | - Dan Siskind
- Metro South Addiction and Mental Health Service, Brisbane, Australia.,Queensland Centre for Mental Health Research and School of Clinical Medicine, University of Queensland, Brisbane, Australia
| | - Abraham Weizman
- Research Unit, Geha Mental Health Center and Molecular Psychiatry Laboratory, Felsenstein Medical Research Center, Tel Aviv, Israel.,Department of Psychiatry Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
| | - Rim Masmoudi
- Psychiatry "A" Department, Hedi Chaker University Hospital, Sfax, Tunisia.,Faculty of Medicine, University of Sfax, Sfax, Tunisia
| | - Shamin Mohd Saffian
- Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | | | - Peter F Buckley
- School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Stephen R Marder
- Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA.,VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA
| | - Leslie Citrome
- New York Medical College, Department of Psychiatry and Behavioral Sciences, Valhalla, NY, USA
| | - Oliver Freudenreich
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA.,Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, New York, USA.,Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany
| | - Daniel J Müller
- Addictions Division, Centre for Addiction and Mental Health, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
14
|
Nakagami Y, Hayakawa K, Horinouchi T, Pereira-Sanchez V, Tan MPJ, Park SC, Park YC, Moon SW, Choi TY, Avasthi A, Grover S, Kallivayalil RA, Rai Y, Shalbafan M, Chongsuksiri P, Udomratn P, Kathriarachchi ST, Xiang YT, Sim K, Javed A, Chong MY, Tan CH, Lin SK, Inada T, Murai T, Kanba S, Sartorius N, Shinfuku N, Kato TA. A Call for a Rational Polypharmacy Policy: International Insights From Psychiatrists. Psychiatry Investig 2021; 18:1058-1067. [PMID: 34732030 PMCID: PMC8600221 DOI: 10.30773/pi.2021.0169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 07/02/2021] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE Recently, rational polypharmacy approaches have been proposed, regardless of the lower risk and cost of monotherapy. Considering monotherapy as first-line treatment and polypharmacy as rational treatment, a balanced attitude toward polypharmacy is recommended. However, the high prevalence of polypharmacy led the Japanese government to establish a polypharmacy reduction policy. Based on this, the association between the policy and psychiatrists' attitude toward polypharmacy has been under debate. METHODS We developed an original questionnaire about Psychiatrists' attitudes toward polypharmacy (PAP). We compared the PAP scores with the treatment decision-making in clinical case vignettes. Multiple regression analyses were performed to quantify associations of explanatory variables including policy factors and PAP scores. The anonymous questionnaires were administered to psychiatrists worldwide. RESULTS The study included 347 psychiatrists from 34 countries. Decision-making toward polypharmacy was associated with high PAP scores. Multiple regression analysis revealed that low PAP scores were associated with the policy factor (β=-0.20, p=0.004). The culture in Korea was associated with high PAP scores (β=0.34, p<0.001), whereas the culture in India and Nepal were associated with low scores (β=-0.15, p=0.01, and β=-0.17, p=0.006, respectively). CONCLUSION Policy on polypharmacy may influence psychiatrists' decision-making. Thus, policies considering rational polypharmacy should be established.
Collapse
Affiliation(s)
- Yukako Nakagami
- Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.,Department of Preventive Services, School of Public Health/Medicine and Medical Science, Kyoto University, Kyoto, Japan
| | - Kohei Hayakawa
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Toru Horinouchi
- Department of Neuroscience, Trafford Centre for Medical Research, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
| | - Victor Pereira-Sanchez
- Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, USA
| | - Marcus P J Tan
- Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK
| | - Seon-Cheol Park
- Department of Psychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Yong Chon Park
- Department of Psychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Seok Woo Moon
- Department of Psychiatry, Konkuk University Chungju Hospital, Institute of Medical Science, Chungju, Republic of Korea
| | - Tae Young Choi
- Department of Psychiatry, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Yugesh Rai
- Essex Partnership University Trust, Colchester, UK
| | | | | | - Pichet Udomratn
- Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
| | - Samudra T Kathriarachchi
- Department of Psychiatry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka
| | - Yu-Tao Xiang
- Unit of Psychiatry, Department of Public Health and Medicinal Administration, University of Macau, Macao SAR, China
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | - Mian-Yoon Chong
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung & Chang Gung University School of Medicine, Taoyuan, Taiwan
| | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Shih-Ku Lin
- Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Toshiya Inada
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Toshiya Murai
- Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Shigenobu Kanba
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
15
|
Yang KC, Liao YT, Yang YK, Lin SK, Liang CS, Bai YM. Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN). CNS Drugs 2021; 35:893-905. [PMID: 34312788 DOI: 10.1007/s40263-021-00838-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/14/2021] [Indexed: 01/22/2023]
Abstract
OBJECTIVE Schizophrenia is a chronic, debilitating psychiatric disorder with a high risk of relapse. Nonadherence to medication is a significant contributor to poor outcomes. Although long-acting injectable (LAI) antipsychotics prevent the relapse of schizophrenia, several factors present obstacles to the use of LAI antipsychotics, and clinical guidelines for LAI antipsychotics remain limited. To provide clinical recommendations, the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) developed consensus statements for the effectiveness, target populations, initiation timing, and particular clinical situations for the use of LAI antipsychotics in patients with schizophrenia. METHODS After a systematic literature review, a working group drafted consensus statements for the selected clinical topics and determined the levels of evidence-based recommendation based on the latest World Federation of Societies of Biological Psychiatry grading system. A scientific committee evaluated the draft statements and decided the final recommendations regarding the grades by anonymous voting after incorporating clinical experience and practice into the evidence from research. RESULTS The TSBPN proposed ten consensus statements for the application of LAI antipsychotics. The current evidence supported that LAI antipsychotics could be a treatment option for all schizophrenia patients, including first-episode patients. LAI antipsychotics could be initiated both during an acute psychotic episode and when patients are stable. The consensus also gave recommendations for particular clinical situations with insufficient scientific data, such as for use in elderly or adolescent patients, patients with treatment-resistant schizophrenia, and breakthrough psychosis, and strategies to assist patients/caregivers with decision making. CONCLUSIONS The consensus statements developed by the TSBPN provide evidence-based clinical recommendations and could give clinicians more confidence when prescribing LAI antipsychotics to treat schizophrenia, thereby improving treatment outcomes.
Collapse
Affiliation(s)
- Kai-Chun Yang
- Department of Psychiatry, Taipei Veterans General Hospital, No. 201, Sec 2, Shih-Pai Rd., Beitou, 11217, Taipei, Taiwan.,Division of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
| | - Yin-To Liao
- Department of Psychiatry, Chung Shan Medical University Hospital, Taichung, Taiwan.,Department of Psychiatry, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
| | - Yen-Kuang Yang
- Department of Psychiatry, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.,Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.,Department of Psychiatry, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Chang Gung Memorial Hospital, Linkou, Taiwan.,Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chih-Sung Liang
- Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, No.60, Xinmin Road, Beitou District, Taipei, 11243, Taiwan. .,Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan.
| | - Ya-Mei Bai
- Department of Psychiatry, Taipei Veterans General Hospital, No. 201, Sec 2, Shih-Pai Rd., Beitou, 11217, Taipei, Taiwan. .,Division of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. .,Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan.
| |
Collapse
|
16
|
Chen WY, Huang MC, Lee YC, Chang CE, Lin SK, Chiu CC, Liu HC, Kuo CJ, Weng SH, Chen PY, Kuo PH. The Heterogeneity of Longitudinal Cognitive Decline in Euthymic Bipolar I Disorder With Clinical Characteristics and Functional Outcomes. Front Psychiatry 2021; 12:684813. [PMID: 34366918 PMCID: PMC8335543 DOI: 10.3389/fpsyt.2021.684813] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 06/24/2021] [Indexed: 12/01/2022] Open
Abstract
We characterized the heterogeneity and risk factors of cognitive decline in euthymic bipolar disorder (BD), and their magnitude of associations with subjective daily functions. In this retrospective cohort, BD type I patients (N = 128) were followed for an average of 6.5 years. Intelligence quotient (IQ) at index date was recorded, and premorbid IQ was estimated. We used Brief Assessment of Cognition in Affective Disorders (BAC-A) to assess cognition at follow-up. We evaluated current functions with World Health Organization Disability Assessment Schedule 2.0. Clinical and sociodemographic factors were examined for their independent effects on longitudinal cognitive decline. In addition, we employed multivariate adaptive regression spline to detect inflection points for the nature of slope changes in cognitive decline among BD patients. During follow-up years, 21 BD patients (16.4%) showed longitudinal cognitive decline. In cognitive decline group, all cognitive domains of BAC-A were significantly worsened. We found that density of episodes with psychotic features was an independent risk factor for cognitive decline after adjusted for age, gender and dose of mood stabilizer. After the age of 42 years, a steeper cognitive change was observed in the cognitive decline group. The correlation pattern between cognitive domains and functional outcomes differed between patients with and without cognitive decline. The present study characterized cognitive heterogeneity longitudinally in BD patients. As density of episodes play roles for cognitive decline, our results emphasize the importance of relapse prevention. Our findings provide hints for future personalized interventions and facilitating genetic and biological studies for dissecting the heterogeneity of bipolar illness.
Collapse
Affiliation(s)
- Wen-Yin Chen
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Ming-Chyi Huang
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Ya-Chin Lee
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Chiao-Erh Chang
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chih Chiang Chiu
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Hsing-Cheng Liu
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chian-Jue Kuo
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Shih-Han Weng
- Department of Education and Research, Taipei City Hospital, Taipei, Taiwan
| | - Po-Yu Chen
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Po-Hsiu Kuo
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
- Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan
| |
Collapse
|
17
|
Chen SY, Chen CH, Lo C, Lu ML, Hsu CD, Chiu YH, Chen CH, Lin SK, Huang MC, Chen HC, Kuo PH. Differential Co-Occurring Patterns Between Depressive Symptomatology and Sleep-Wake-Related Disturbances in Mood Disorders. Nat Sci Sleep 2021; 13:503-514. [PMID: 33948093 PMCID: PMC8088296 DOI: 10.2147/nss.s301357] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 04/09/2021] [Indexed: 01/01/2023] Open
Abstract
PURPOSE This study aimed to elucidate the various co-occurring patterns of depressive symptomatology and sleep-wake-related disturbances (SWRDs) in patients with mood disorders. PATIENTS AND METHODS Individuals in non-acute states of major depressive disorder or bipolar disorder were recruited. The Beck Depression Inventory II (BDI-II) was utilized to evaluate depressive symptoms. BDI-II items were classified into three domains: cognitive, affective, and somatic. Between-domain differences with various SWRDs were examined. Latent class analysis was used to empirically classify participants using BDI-II items as indicator variables. Co-occurring patterns between domains of BDI-II items and SWRDs were re-examined in each subgroup to elucidate inter-individual differences. RESULTS In total, 657 participants were enrolled. Of participants, 66.8% were female, and 52.4% were diagnosed with major depressive disorder. Each BDI-II domain exhibited different co-occurring patterns. The somatic domain was most likely to co-occur with various SWRDs. Three subgroups were derived from latent class analysis and were designated as poor sleep quality and high insomnia (n=150), poor sleep quality and moderate insomnia (n=248), and poor sleep quality and low insomnia (n=159). The group with more severe insomnia presented with more severe depressive and anxiety symptoms. The three subgroups further differed in co-occurring patterns. From the low insomnia to high insomnia group, the associations with various SWRDs appeared in the sequence of somatic, affective, and cognitive domains. CONCLUSION Co-occurring patterns between domains of depressive symptomatology with various SWRDs differ and may vary among individuals.
Collapse
Affiliation(s)
- Sze-Yu Chen
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan
| | - Chun-Hao Chen
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan
| | - Chen Lo
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan
| | - Mong-Liang Lu
- Department of Psychiatry, Wan-Fang Hospital & School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Cheng-Dien Hsu
- Department of Psychosomatic Medicine, Taiwan Adventist Hospital, Taipei, Taiwan
| | - Yi-Hang Chiu
- Department of Psychiatry, Wan-Fang Hospital & School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chun-Hsin Chen
- Department of Psychiatry, Wan-Fang Hospital & School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.,Department of Psychiatry, Taipei City Hospital, Songde Branch, Taipei, Taiwan
| | - Ming-Chyi Huang
- Department of Psychiatry, Taipei City Hospital, Songde Branch, Taipei, Taiwan
| | - Hsi-Chung Chen
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan.,Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan
| | - Po-Hsiu Kuo
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan.,Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
18
|
Hagi K, Lin SK, Yeh CB. Lurasidone switching in patients with schizophrenia who showed suboptimal effect and/or intolerability to current antipsychotics: A multi-center, open-label, single-arm, flexible dose study. Taiwan J Psychiatry 2021. [DOI: 10.4103/tpsy.tpsy_26_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
19
|
Park SC, Kim GM, Kato TA, Chong MY, Lin SK, Yang SY, Avasthi A, Grover S, Kallivayalil RA, Xiang YT, Chee KY, Tanra AJ, Tan CH, Sim K, Sartorius N, Shinfuku N, Park YC, Inada T. Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychotics. Nord J Psychiatry 2021; 75:9-17. [PMID: 32580668 DOI: 10.1080/08039488.2020.1777462] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND Network analysis provides a new viewpoint that explicates intertwined and interrelated symptoms into dynamic causal architectures of symptom clusters. This is a process called 'symptomics' and is concurrently applied to various areas of symptomatology. AIMS Using the data from Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), we aimed to estimate a network model of extrapyramidal syndrome in patients with schizophrenia. METHODS Using data from REAP-AP, extrapyramidal symptoms of 1046 Asian patients with schizophrenia were evaluated using the nine items of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). The estimated network of the ordered-categorical DIEPSS items consisted of nodes (symptoms) and edges (interconnections). A community detection algorithm was also used to identify distinctive symptom clusters, and correlation stability coefficients were used to evaluate the centrality stability. RESULTS An interpretable level of node strength centrality was ensured with a correlation coefficient. An estimated network of extrapyramidal syndrome showed that 26 (72.2%) of all possible 35 edges were estimated to be greater than zero. Dyskinesia was most centrally situated within the estimated network. In addition, earlier antipsychotic-induced extrapyramidal symptoms were divided into three distinctive clusters - extrapyramidal syndrome without parkinsonism, postural instability and gait difficulty-dominant parkinsonism, and tremor-dominant parkinsonism. CONCLUSIONS Our findings showed that dyskinesia is the most central domain in an estimated network structure of extrapyramidal syndrome in Asian patients with schizophrenia. These findings are consistent with the speculation that acute dystonia, akathisia, and parkinsonism could be the risk factors of tardive dyskinesia.
Collapse
Affiliation(s)
- Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Gyung-Mee Kim
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | - Mian-Yoon Chong
- Chang Gung Memorial Hospital, Chiayi, Taiwan.,School of Medicine, Chang Gung University, Kwei-Shan, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital, Songde Branch, Taipei, Taiwan
| | - Shu-Yu Yang
- Department of Pharmacy, Tapei City Hospital, Songde Branch, Tapei, Taiwan
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | | | - Yu-Tao Xiang
- Center for Cognition and Brain Sciences, University of Macau, Macao SAR, China
| | - Kok Yoon Chee
- Tunku Abdul Rahman Institute of Neuroscience, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
| | | | - Chay Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore, Singapore
| | - Kang Sim
- West Region, Institute of Mental Health and Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Toshiya Inada
- Department of Psychiatry and Psychobiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
20
|
Tang CT, Chua EC, Chew QH, He YL, Si TM, Chiu HFK, Xiang YT, Kato TA, Kanba S, Shinfuku N, Lee MS, Park SC, Park YC, Chong MY, Lin SK, Yang SY, Tripathi A, Avasthi A, Grover S, Kallivayalil RA, Udomratn P, Chee KY, Tanra AJ, Rabbani MG, Javed A, Kathiarachchi S, Waas D, Myint WA, Sartorius N, Tran VC, Nguyen KV, Tan CH, Baldessarini RJ, Sim K. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia Pac Psychiatry 2020; 12:e12393. [PMID: 32468725 DOI: 10.1111/appy.12393] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Accepted: 04/24/2020] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Patterns of clinical use of long-acting injectable (LAI) antipsychotic drugs in many countries, especially in Asia, for treatment of patients diagnosed with chronic psychotic disorders including schizophrenia are not well established. METHODS Within an extensive research consortium, we evaluated prescription rates for first- (FGA) and second-generation antipsychotic (SGA) LAI drugs and their clinical correlates among 3557 subjects diagnosed with schizophrenia across 15 Asian countries and region. RESULTS Overall, an average of 17.9% (638/3557; range: 0.0%-44.9%) of treated subjects were prescribed LAI antipsychotics. Those given LAI vs orally administered agents were significantly older, had multiple hospitalizations, received multiple antipsychotics more often, at 32.4% higher doses, were more likely to manifest disorganized behavior or aggression, had somewhat superior psychosocial functioning and less negative symptoms, but were more likely to be hospitalized, with higher BMI, and more tremor. Being prescribed an FGA vs SGA LAI agent was associated with male sex, aggression, disorganization, hospitalization, multiple antipsychotics, higher doses, with similar risks of adverse neurological or metabolic effects. Rates of use of LAI antipsychotic drugs to treat patients diagnosed with schizophrenia varied by more than 40-fold among Asian countries and given to an average of 17.9% of treated schizophrenia patients. We identified the differences in the clinical profiles and treatment characteristics of patients who were receiving FGA-LAI and SGA-LAI medications. DISCUSSION These findings behoove clinicians to be mindful when evaluating patients' need to be on LAI antipsychotics amidst multifaceted considerations, especially downstream adverse events such as metabolic and extrapyramidal side effects.
Collapse
Affiliation(s)
- Chao Tian Tang
- Institute of Mental Health, Buangkok Green Medical Park, Singapore, Singapore
| | - Ee Cheong Chua
- Institute of Mental Health, Buangkok Green Medical Park, Singapore, Singapore
| | - Qian Hui Chew
- Institute of Mental Health, Buangkok Green Medical Park, Singapore, Singapore
| | - Yan-Ling He
- Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
| | - Tian-Mei Si
- Institute of Mental Health, Peking University, Beijing, China
| | - Helen F-K Chiu
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Yu-Tao Xiang
- Centre for Cognition and Brain Sciences, University of Macau, Macao SAR, China
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | - Shigenobu Kanba
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | | | - Min-Soo Lee
- Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
| | - Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, South Korea
| | - Yong-Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, South Korea
| | - Mian-Yoon Chong
- Department of Psychiatry, Kaoshiung Chang Gung Memorial Hospital and Chang Gung University School of Medicine, Kaohsiung, Taiwan
| | - Shih-Ku Lin
- Department of Pharmacy, Taipei City Hospital and Fu Jen University, Taipei, Taiwan
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital and Fu Jen University, Taipei, Taiwan
| | - Adarsh Tripathi
- Department of Psychiatry, King George's Medical University, Lucknow, India
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Roy A Kallivayalil
- Department of Psychiatry, Pushpagiri Institute of Medical Sciences, Tiruvalla, India
| | - Pichet Udomratn
- Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Kok Yoon Chee
- Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur, Malaysia
| | - Andi J Tanra
- Department of Psychiatry, Hasanuddin University Faculty of Medicine, Makassar, Indonesia
| | | | - Afzal Javed
- Pakistan Psychiatric Research Center, Fountain House, Lahore, Pakistan
| | | | - Dulshika Waas
- Department of Psychiatry, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
| | - Wing Aung Myint
- Mental Health Society, Myanmar Medical Association, Yangon, Myanmar
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Van Cuong Tran
- Vietnam Psychiatric Association (VPA), Thuong Tin, Hanoi, Vietnam
| | - Kim Viet Nguyen
- Vietnam Psychiatric Association (VPA), Thuong Tin, Hanoi, Vietnam
| | - Chay-Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore, Singapore
| | - Ross J Baldessarini
- International Consortium for Mood & Psychotic Disorder Research, McLean Hospital, Belmont, Massachusetts, USA
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore, Singapore
| |
Collapse
|
21
|
Lim WK, Chew QH, He YL, Si TM, Chiu FKH, Xiang YT, Kato TA, Kanba S, Shinfuku N, Lee MS, Park SC, Park YC, Chong MY, Lin SK, Yang SY, Tripathi A, Avasthi A, Grover S, Kallivayalil RA, Udomratn P, Chee KY, Tanra AJ, Rabbani MG, Javed A, Kathiarachchi S, Waas D, Myint WA, Sartorius N, Tran VC, Nguyen KV, Tan CH, Baldessarini RJ, Sim K. Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study. Hum Psychopharmacol 2020; 35:1-7. [PMID: 32738085 DOI: 10.1002/hup.2752] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Revised: 06/11/2020] [Accepted: 06/24/2020] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Studies examining coprescription and dosages of mood stabilizers (MSs) with antipsychotics for psychotic disorders are infrequent. Based on sparse extant data and clinical experience, we hypothesized that adjunctive MS use would be associated with certain demographic (e.g., younger age), clinical factors (e.g., longer illness duration), and characteristics of antipsychotic treatment (e.g., multiple or high antipsychotic doses). METHODS Within an Asian research consortium focusing on pharmaco-epidemiological factors in schizophrenia, we evaluated rates of MS coprescription, including high doses (>1000 mg/day lithium-equivalents) and clinical correlates. RESULTS Among 3557 subjects diagnosed with schizophrenia in 14 Asian countries, MSs were coprescribed with antipsychotics in 13.6% (n = 485) of the sample, with 10.9% (n = 53) on a high dose. Adjunctive MS treatment was associated (all p < 0.005) with demographic (female sex and younger age), setting (country and hospitalization), illness (longer duration, more hospitalizations, non-remission of illness, behavioral disorganization, aggression, affective symptoms, and social-occupational dysfunction), and treatment-related factors (higher antipsychotic dose, multiple antipsychotics, higher body mass index, and greater sedation). Patients given high doses of MSs had a less favorable illness course, more behavioral disorganization, poorer functioning, and higher antipsychotic doses. CONCLUSIONS Schizophrenia patients receiving adjunctive MS treatment in Asian psychiatric centers are more severely ill and less responsive to simpler treatment regimens.
Collapse
Affiliation(s)
| | | | - Yan-Ling He
- Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
| | - Tian-Mei Si
- Institute of Mental Health, Peking University, Beijing, China
| | | | - Yu-Tao Xiang
- Faculty of Health Sciences, University of Macau, Macau, China
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | - Shigenobu Kanba
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | | | - Min-Soo Lee
- Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
| | - Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, South Korea
| | - Yong-Chon Park
- Department of Psychiatry, Hanyang University, Seoul, South Korea
| | - Mian-Yoon Chong
- Department of Psychiatry, Kaoshiung Chang Gung Memorial Hospital and Chang Gung University School of Medicine, Kaohsiung, Taiwan
| | - Shih-Ku Lin
- Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Shu-Yu Yang
- Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Adarsh Tripathi
- Department of Psychiatry, King George's Medical University, Lucknow, India
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | | | - Pichet Udomratn
- Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Kok Yoon Chee
- Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur, Malaysia
| | - Andi J Tanra
- Department of Psychiatry, Hasanuddin University Faculty of Medicine, Makassar, Indonesia
| | | | - Afzal Javed
- Pakistan Psychiatric Research Center, Fountain House, Lahore, Pakistan
| | | | - Dulshika Waas
- Department of Psychiatry, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
| | - Wing Aung Myint
- Mental Health Society, Myanmar Medical Association, Yangon, Myanmar
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | | | | | - Chay-Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore, Singapore
| | - Ross J Baldessarini
- International Consortium for Mood & Psychotic Disorder Research, McLean Hospital, Belmont, Massachusetts, USA
| | - Kang Sim
- Institute of Mental Health, Singapore, Singapore
| |
Collapse
|
22
|
Park SC, Lee BJ, Park JH, Kawasaki H, Avasthi A, Grover S, Tanra AJ, Lin SK, Javed A, Tan CH, Sartorius N, Shinfuku N, Park YC. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. Kaohsiung J Med Sci 2020; 36:1030-1037. [PMID: 32772489 DOI: 10.1002/kjm2.12280] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 06/16/2020] [Accepted: 07/05/2020] [Indexed: 11/08/2022] Open
Abstract
Although the association between antipsychotic use and corrected QT interval (QTc) prolongation has been repeatedly confirmed, the relationship has been rarely studied in a practical setting. Using data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP) survey, our study aimed to investigate the prevalence and clinical correlates of QTc prolongation in 2553 Asian patients with schizophrenia. After adjusting for the potential effect of confounding factors, the baseline and clinical characteristics of the schizophrenia patients with and without QTc prolongation were compared using analyses of covariance and binary logistic analyses. In addition, a binary logistic analysis model with a forward selection method was used to identify the distinctive clinical correlates of QTc prolongation. QTc prolongation was noted in 1.1% of Asian patients with schizophrenia. Schizophrenia patients were characterized by lower proportions of disorganized speech and negative symptoms; higher use of amisulpride and clozapine; and higher proportions of rigidity, hypercholesterolemia, and sedation than those without QTc prolongation. Finally, a binary logistic mode showed that amisulpride, clozapine, rigidity, and hypercholesterolemia might be the distinctive clinical correlates of QTc prolongation in Asian patients with schizophrenia. These findings indicate the clinical implications that the uses of amisulpride and clozapine and the occurrences of rigidity and hypercholesterolemia may be potential risk factors for QTc prolongation of schizophrenia patients.
Collapse
Affiliation(s)
- Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Bong Ju Lee
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Jae Hong Park
- Department of Psychiatry, College of Medicine, Dong-A University, Busan, Republic of Korea
| | - Hiroaki Kawasaki
- Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Andi J Tanra
- Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
| | - Shih-Ku Lin
- Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | - Chay Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore, Singapore
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| |
Collapse
|
23
|
Park SC, Jang EY, Xiang YT, Kanba S, Kato TA, Chong MY, Lin SK, Yang SY, Avasthi A, Grover S, Kallivayalil RA, Udomratn P, Chee KY, Tanra AJ, Tan CH, Sim K, Sartorius N, Park YC, Shinfuku N. Network analysis of the depressive symptom profiles in Asian patients with depressive disorders: Findings from the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD). Psychiatry Clin Neurosci 2020; 74:344-353. [PMID: 32048773 PMCID: PMC7318233 DOI: 10.1111/pcn.12989] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 01/21/2020] [Accepted: 02/04/2020] [Indexed: 12/13/2022]
Abstract
AIM We aimed to estimate the network structures of depressive symptoms using network analysis and evaluated the geographic regional differences in theses network structures among Asian patients with depressive disorders. METHODS Using data from the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD), the network of the ICD-10 diagnostic criteria for depressive episode was estimated from 1174 Asian patients with depressive disorders. The node strength centrality of all ICD-10 diagnostic criteria for a depressive episode was estimated using a community-detection algorithm. In addition, networks of depressive symptoms were estimated separately among East Asian patients and South or Southeast Asian patients. Moreover, networks were estimated separately among Asian patients from high-income countries and those from middle-income countries. RESULTS Persistent sadness, fatigue, and loss of interest were the most centrally situated within the network of depressive symptoms in Asian patients with depressive disorders overall. A community-detection algorithm estimated that when excluding psychomotor disturbance as an outlier, the other nine symptoms formed the largest clinically meaningful cluster. Geographic and economic variations in networks of depressive symptoms were evaluated. CONCLUSION Our findings demonstrated that the typical symptoms of the ICD-10 diagnostic criteria for depressive episode are the most centrally situated within the network of depressive symptoms. Furthermore, our findings suggested that cultural influences related to geographic and economic distributions of participants could influence the estimated depressive symptom network in Asian patients with depressive disorders.
Collapse
Affiliation(s)
- Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Eun Young Jang
- Department of Counseling Psychology, Honam University College of Humanities and Social Sciences, Gwangju, Republic of Korea
| | - Yu-Tao Xiang
- Faculty of Health Sciences, University of Macau, Macau, China
| | - Shigenobu Kanba
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | - Takahiro A Kato
- Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
| | - Mian-Yoon Chong
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung & Chang Gung University School of Medicine, Linkou, Taiwan
| | - Shih-Ku Lin
- Psychiatry Center, Tapei City Hospital, Taipei, Taiwan
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital and Fu Jen University, Taipei, Taiwan
| | - Ajit Avasthi
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | - Sandeep Grover
- Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
| | | | - Pichet Udomratn
- Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Kok Yoon Chee
- Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur, Malaysia
| | - Andi J Tanra
- Faculty of Medicine, Department of Psychiatry, Hasanuddin University, Makassar, Indonesia
| | - Chay-Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| |
Collapse
|
24
|
Xu SW, Dong M, Zhang Q, Yang SY, Chen LY, Sim K, He YL, Chiu HF, Sartorius N, Tan CH, Chong MY, Shinfuku N, Lin SK, Ng CH, Ungvari GS, Najoan E, Kallivayalil RA, Jamaluddin R, Javed A, Iida H, Swe T, Zhang B, Xiang YT. Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016). Psychiatry Res 2020; 287:112271. [PMID: 30885383 DOI: 10.1016/j.psychres.2019.02.056] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 02/20/2019] [Accepted: 02/20/2019] [Indexed: 10/27/2022]
Abstract
Clozapine is an effective antipsychotic medication for treatment resistant schizophrenia and is widely used in Asian countries. This study investigated clozapine prescription patterns and their associated factors in Asian countries and territories based on the database of the Research on Asian Psychotropic prescription study (REAP) conducted in 2016. Demographic and clinical information of 3744 schizophrenia patients in 15 Asian countries and territories was collected with a standardized data collection form. In total, 18.4% of the sample received clozapine, ranging from 2.6% in Japan to 32.3% in Hong Kong. Binary logistic regression analysis revealed that higher antipsychotic dose (OR = 1.002, P < 0.001), less frequent first admission in the sample (OR = 0.6, P < 0.001), more severe negative symptoms (OR = 1.4, P = 0.001) and less first generation antipsychotics (FGAs) (OR = 0.2, P < 0.001) were independently and significantly associated with clozapine prescription. Clozapine is frequently and increasingly prescribed for schizophrenia in Asia, with large variation across countries and territories. Given the diverse prescription patterns of clozapine found in Asian countries/territories, the clinical rationale of clozapine prescription needs careful consideration in Asia with more local input.
Collapse
Affiliation(s)
- Shi-Wei Xu
- Department of Psychiatry and Psychology, Southern Medical University Nanfang Hospital, Guangdong, China; Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, China
| | - Min Dong
- Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macao SAR, China
| | - Qinge Zhang
- The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, School of Mental Health, Beijing, China
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan
| | - Lian-Yu Chen
- Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Kang Sim
- Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Yan-Ling He
- Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
| | - Helen Fk Chiu
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- Chiayi Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Chiayi, Taiwan
| | - Naotaka Shinfuku
- International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan
| | - Shih-Ku Lin
- Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chee H Ng
- Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
| | - Gabor S Ungvari
- University of Notre Dame Australia, Fremantle, Australia; Division of Psychiatry, School of Medicine, University of Western Australia, Perth, Australia
| | | | | | - Ruzita Jamaluddin
- Department of Psychiatry & Mental Health, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | - Hitoshi Iida
- Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Thiha Swe
- Department of Mental Health, University of Medicine, Magway, Myanmar
| | - Bin Zhang
- Department of Psychiatry and Psychology, Southern Medical University Nanfang Hospital, Guangdong, China; Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, China.
| | - Yu-Tao Xiang
- Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macao SAR, China.
| |
Collapse
|
25
|
Chiu EC, Lai KY, Lin SK, Tang SF, Lee SC, Hsieh CL. Construct Validity and Reliability of the Comprehensive Occupational Therapy Evaluation Scale (COTES) in People With Schizophrenia. Am J Occup Ther 2020; 73:7306205060p1-7306205060p8. [PMID: 31891345 DOI: 10.5014/ajot.2019.026807] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE We evaluated the construct validity (i.e., unidimensionality and convergent validity) and Rasch reliability of the 20-item Comprehensive Occupational Therapy Evaluation Scale (COTES) in people with schizophrenia. METHOD Retrospective chart review was used to collect COTES data from 505 inpatients with schizophrenia. For construct validity, we first examined unidimensionality of each of the three COTES subscales using Rasch analysis. After unidimensionality was supported, we examined convergent validity using Pearson's r and Rasch reliability of the individual subscales. RESULTS After deleting two misfitting items, the remaining items (i.e., the COTES-18) showed unidimensionality. Infit and outfit mean squares were 0.73-1.25. Moderate correlations were found among the three COTES-18 subscales (rs = .57-.71). The Rasch reliabilities of the three subscales were .83-.92. CONCLUSION The COTES-18 has sufficient construct validity and reliability to assess three specific dimensions of behavior affecting occupational performance in people with schizophrenia.
Collapse
Affiliation(s)
- En-Chi Chiu
- En-Chi Chiu, OTD, PhD, is Associate Professor, Department of Long-Term Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
| | - Kuan-Yu Lai
- Kuan-Yu Lai, MS, is Occupational Therapist, Department of Occupational Therapy, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Shih-Ku Lin
- Shih-Ku Lin, MD, is Psychiatrist, Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Shih-Fen Tang
- Shih-Fen Tang, MS, is Occupational Therapist, Department of Occupational Therapy, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan, Taiwan
| | - Shu-Chun Lee
- Shu-Chun Lee, MS, is Doctoral Candidate, School of Occupational Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan, and Occupational Therapist, Department of Occupational Therapy, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan;
| | - Ching-Lin Hsieh
- Ching-Lin Hsieh, PhD, is Professor, School of Occupational Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan, and Adjunct Professor, Department of Occupational Therapy, College of Medical and Health Science, Asia University, Taichung, Taiwan
| |
Collapse
|
26
|
Huang MC, Chen CH, Chen LY, Chang HM, Chen CK, Lin SK, Xu K. Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation. Psychopharmacology (Berl) 2020; 237:45-53. [PMID: 31377886 DOI: 10.1007/s00213-019-05342-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Accepted: 07/25/2019] [Indexed: 01/24/2023]
Abstract
BACKGROUND Ketamine has emerged as a major substance of abuse worldwide. Evidence suggests a role of orexin system in reward processing, withdrawal, and stress response. It also interacts with the stress mechanisms of hypothalamic-pituitary-adrenal (HPA) axis to regulate drug-taking behavior. The study aimed to explore the relevance of orexin and stress hormones to chronic ketamine abuse. METHODS We enrolled 67 ketamine-dependent (KD) patients and 64 controls. The levels of orexin-A, adrenocorticotropic hormone (ACTH), and cortisol were measured at baseline, 1 week, and 2 weeks after ketamine discontinuation. KD patients were assessed by Beck Depression Inventory, Beck Anxiety Inventory, and Visual Analogue Scale for ketamine craving at baseline. RESULTS Compared with the controls, KD patients had significantly lower orexin-A (0.65 ± 0.12 vs. 0.74 ± 0.10 ng/mL, p < 0.001) and increased ACTH (32.3 ± 16.3 vs. 22.3 ± 11.0 pg/mL, p = 0.008) levels at baseline, whereas cortisol levels were similar between two groups. Levels of the three markers did not correlate with ketamine use variables, craving, depression, or anxiety symptoms. The levels did not alter after 1 or 2 weeks of ketamine discontinuation. Notably, those with higher anxiety had lower orexin-A but increased cortisol levels than did those with lower anxiety. CONCLUSIONS This study showed that KD patients had persistent orexin-A reduction and stress hormone dysregulation in early abstinence. The anxious phenotype of KD might be associated with a lower orexin-A expression. These results point to a promising pathway to investigate the neurochemical mechanisms of ketamine addiction.
Collapse
Affiliation(s)
- Ming-Chyi Huang
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, 309, Song-De Road, Xinyi District, Taipei City, 110, Taiwan.,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Xing St., Taipei, 110, Taiwan.,Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan
| | - Chun-Hsin Chen
- Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.,Department of Psychiatry, Wan-Fang Hospital, Taipei Medical University, 111, Sec. 3, Hsing-Long Rd, Taipei, 116, Taiwan
| | - Lian-Yu Chen
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, 309, Song-De Road, Xinyi District, Taipei City, 110, Taiwan.,Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan
| | - Hu-Ming Chang
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, 309, Song-De Road, Xinyi District, Taipei City, 110, Taiwan
| | - Chih-Ken Chen
- Department of Psychiatry & Community Medicine Research Center, Chang Gung Memorial Hospital, 200, Ln 208, Ji-Jing 1st Rd, Keelung, Taiwan. .,Chang Gung University School of Medicine, 5, Fu-Hsing Rd, Gue-Shan District Taoyuan City, 333, Taiwan.
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, 309, Song-De Road, Xinyi District, Taipei City, 110, Taiwan. .,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Xing St., Taipei, 110, Taiwan.
| | - Ke Xu
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
27
|
Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, Cosca R, Wang L, Suchkov Y, Agarkov A, Watabe K, Matsui T, Sato T, Inoue Y, Higuchi T, Correll CU, Kane JM. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res 2020; 215:408-415. [PMID: 31471246 DOI: 10.1016/j.schres.2019.07.055] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 07/26/2019] [Accepted: 07/29/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. This study determined the efficacy, safety and pharmacokinetics of a blonanserin transdermal patch in patients with acutely exacerbated schizophrenia. METHODS This double-blind, multicenter, phase 3 study consisted of a 1-week observation period during which patients were treated with two patches of placebo, followed by a 6-week double-blind period where patients were randomized (1:1:1) to receive once-daily blonanserin 40 mg, blonanserin 80 mg, or placebo patches. The primary endpoint was the change from baseline in the total Positive and Negative Symptom Scale (PANSS) score. Safety assessments included treatment-emergent adverse events (TEAEs). RESULTS Between December 2014 and October 2018, patients were recruited and randomly assigned to blonanserin 40 mg (n = 196), blonanserin 80 mg (n = 194), or placebo (n = 190); of these, 77.2% completed the study. Compared with placebo, blonanserin significantly improved PANSS total scores at 6 weeks (least square mean [LSM] difference vs placebo: -5.6 with blonanserin 40 mg; 95% confidence interval [CI] -9.6, -1.6; adjusted p = 0.007, and - 10.4 with blonanserin 80 mg; 95% CI -14.4, -6.4; adjusted p < 0.001). Blonanserin was well tolerated; the most common TEAEs reported were application-site erythema and pruritus, akathisia, tremor, and insomnia. CONCLUSIONS Blonanserin transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability.
Collapse
Affiliation(s)
- Nakao Iwata
- Department of Psychiatry, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake-shi, Aichi 470-1192, Japan.
| | - Jun Ishigooka
- Institute of CNS Pharmacology, 4-26-11, Sendagaya, Shibuya-Ku, Tokyo 151-0051, Japan.
| | - Won-Hyoung Kim
- Department of Psychiatry, Inha University Hospital, 27, Inhang-ro, Jung-gu Incheon, 22332, Republic of Korea
| | - Bo-Hyun Yoon
- Department of Psychiatry, Naju National Hospital, 1328-31 Senam-ro, Sanpo-myeon, Naju-City, Jeonnam 58213, Republic of Korea.
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, No.309, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan, ROC.
| | - Ahmad Hatim Sulaiman
- Department of Psychological Medicine, University Malaya Medical Centre, 50603 Kuala Lumpur, Malaysia.
| | - Rowena Cosca
- Department of Psychiatry, Western Visayas Medical Center, Q. Abeto St., Mandurriao, Iloilo City 5000, Philippines
| | - Lina Wang
- Department of Mood Disorders, Tianjin Anding Hospital, Liulin Road 13, Hexi District, Tianjin 300222, China
| | - Yury Suchkov
- Departments of Psychiatric Hospital, SBHI of Nizhny Novgorod Region "Clinical Psychiatric Hospital No. 1 of Nizhny Novgorod", 41 Ulianova St., Nizhny Novgorod 603155, Russia
| | - Alexey Agarkov
- Research Center of Mental Health, Tomsk National Research Medical Center, Russian Academy of Sciences, 4 Aleutskaya St., Tomsk 634014, Russia
| | - Kei Watabe
- Sumitomo Dainippon Pharma Co., Ltd., 13-1, Kyobashi 1-Chome, Chuo-ku, Tokyo 104-8356, Japan
| | - Tomohito Matsui
- Sumitomo Dainippon Pharma Co., Ltd., 13-1, Kyobashi 1-Chome, Chuo-ku, Tokyo 104-8356, Japan
| | - Takayuki Sato
- Sumitomo Dainippon Pharma Co., Ltd., 13-1, Kyobashi 1-Chome, Chuo-ku, Tokyo 104-8356, Japan
| | - Yoshifumi Inoue
- Sumitomo Dainippon Pharma Co., Ltd., 13-1, Kyobashi 1-Chome, Chuo-ku, Tokyo 104-8356, Japan.
| | - Teruhiko Higuchi
- Japan Depression Center, 1-7, Rokubancho, Chiyoda-ku, Tokyo 102-0085, Japan
| | - Christoph U Correll
- Department of Psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 75-59 263rd Street Glen Oaks, New York 11004, USA; Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; Department of Psychiatry, Hofstra Northwell School of Medicine, Hempstead, NY, USA; Department of Psychiatry, The Zucker Hillside Hospital, 75-59 263rd Street Glen Oaks, New York 11004, USA; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
| | - John M Kane
- Department of Psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 75-59 263rd Street Glen Oaks, New York 11004, USA; Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; Department of Psychiatry, Hofstra Northwell School of Medicine, Hempstead, NY, USA; Department of Psychiatry, The Zucker Hillside Hospital, 75-59 263rd Street Glen Oaks, New York 11004, USA
| |
Collapse
|
28
|
de Leon J, Rajkumar AP, Kaithi AR, Schoretsanitis G, Kane JM, Wang CY, Tang YL, Lin SK, Hong KS, Farooq S, Ng CH, Ruan CJ, Andrade C. Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. Indian J Psychol Med 2020; 42:4-10. [PMID: 31997860 PMCID: PMC6970303 DOI: 10.4103/ijpsym.ijpsym_379_19] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2019] [Revised: 09/24/2019] [Accepted: 10/07/2019] [Indexed: 12/12/2022] Open
Abstract
Since 1997, studies have found that Asians need lower clozapine doses than Caucasians. Caucasians with average clozapine metabolism may need from 300 to 600 mg/day to reach the therapeutic range (350 ng/ml). Thus, serum clozapine concentration-to-dose (C/D) ratios typically range between 0.60 (male smokers) and 1.20 (female non-smokers). A 2019 systematic review of clozapine levels demonstrated weighted mean C/D ratios of 1.57 in 876 East Asians and 1.07 in 1147 Caucasians (P < .001). In Asian countries, average clozapine doses are lower than 300 mg/day. After sex and smoking stratification in 5 Asian samples with clozapine concentrations, the clozapine dose required to reach 350 ng/ml in female non-smokers ranged from 145 to 189 mg/day and in male smokers, from 259 to 294 mg/day. Thus, in Asian patients with average metabolism (with no inducers other than smoking, with no inhibitors, and in the absence of extreme obesity), the dose needed for clinical response may range between 150 mg/day for female non-smokers to 300 mg/day for male smokers. Clozapine levels may help personalize dosing in clozapine poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Asian PMs may need very low doses (50-150 mg/day) to obtain therapeutic concentrations. About 10% (range 2-13%) of Asians are genetic PM cases. Other PMs are patients taking CYP1A2 inhibitors such as fluvoxamine, oral contraceptives, and valproate. Temporary clozapine PM status may occur during severe systemic infections/inflammations with fever and C-reactive protein (CRP) elevations. Asian UMs include patients taking potent inducers such as phenytoin, and rarely, valproate.
Collapse
Affiliation(s)
- Jose de Leon
- Mental Health Research Center, Eastern State Hospital, Lexington, Kentucky, USA.,Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain, and Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain
| | - Anto P Rajkumar
- Department of Psychiatry, Christian Medical College, Vellore, Tamil Nadu, India.,Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom
| | | | - Georgios Schoretsanitis
- Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA
| | - John M Kane
- Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA.,Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA
| | - Chuan-Yue Wang
- Department of Psychiatry, The National Clinical Research Centre for Mental Disorders and Beijing Key Lab of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Yi-Lang Tang
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, and Substance Abuse Treatment Program, Atlanta VA Medical Center, Decatur, Georgia, USA
| | - Shih-Ku Lin
- Department of General Psychiatry, Taipei City, Psychiatric Center, Taipei, Taiwan, and Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Kyung Sue Hong
- Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
| | - Saeed Farooq
- School of Primary, Community and Social Care, Faulty of Medicine and Health Sciences, Keele University, Staffordshire, and Midlands Partnership NHS Foundation Trust, Staffordshire, United Kingdom
| | - Chee H Ng
- Department of Psychiatry, The Melbourne Clinic and St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
| | - Can-Jun Ruan
- Laboratory of Clinical Psychopharmacology & The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Chittaranjan Andrade
- Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
| |
Collapse
|
29
|
Abstract
The term polypharmacy was originally coined to refer to problems related to multiple drug consumption and excessive drug use during the treatment of a disease or disorder. In the treatment of schizophrenia, polypharmacy usually refers to the simultaneous use of 2 or more antipsychotic medications or combined (adjunct) medications such as mood stabilizers, antidepressants, anxiolytics, or hypnotics in addition to single or multiple antipsychotics. Two decades ago, antipsychotic polypharmacy was criticized as being more expensive, having unproven efficacy, and causing more side effects. However, in recent years, antipsychotic polypharmacy has become more or less acceptable in the views of clinical practitioners and academic researchers. Results from recent reviews have suggested that the common practice of antipsychotic polypharmacy lacks double-blind or high-quality evidence of efficacy, except for negative symptom reduction with aripiprazole augmentation. We reviewed some representative studies that enrolled large numbers of patients and compared antipsychotic polypharmacy and monotherapy during the past decade. The results revealed that a certain proportion of select patients can benefit from antipsychotic polypharmacy without further negative consequences. Because most of the current treatment guidelines from different countries and organizations prefer monotherapy and discourage all antipsychotic polypharmacy, guidelines regarding the use of antipsychotic polypharmacy in clinical practice should be revised. On the basis of the findings of 2 large-scale studies from Asia and Europe, we also suggest ideal rates of various maintenance treatments of schizophrenia, which are as follows: antipsychotic polypharmacy, 30%; combined mood stabilizer, 15%; combined antidepressant, 10%; combined anxiolytics, 30%; and combined hypnotic, 10%.
Collapse
Affiliation(s)
- Shih-Ku Lin
- Department of Psychiatry, School of Medicine, Taipei Medical University and Department of Psychiatry, Taipei City Hospital and Psychiatry Center, Taipei, Taiwan,Correspondence: Dr Shih-Ku Lin, Taipei City Hospital and Psychiatric Center, 309 Songde Road, Xinyi District, Taipei 110, Taiwan ()
| |
Collapse
|
30
|
Tang WK, Lau CG, Ungvari GS, Lin SK, Lane HY. Recovery of cognitive functioning following abstinence from ketamine. Addict Behav 2019; 99:106081. [PMID: 31470241 DOI: 10.1016/j.addbeh.2019.106081] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 08/06/2019] [Accepted: 08/06/2019] [Indexed: 11/15/2022]
Abstract
BACKGROUND Acute and adverse effects of ketamine on cognitive functioning have been documented. No longitudinal study has examined whether cognitive deficits can be reversed following ketamine abstinence although it has been suggested in some cross-sectional studies. This study aimed to investigate the changes in cognitive functioning among ketamine users following a 12-week abstinence from ketamine. METHODS In this longitudinal study, 114 ketamine users completed clinical and cognitive assessments at both baseline and 12-week follow-up with the following instruments: Severity of Dependence Scale, Beck Depression Inventory (BDI), Anxiety Subscale of the Hospital Anxiety Depression Scale (HADSA), and a cognitive battery. RESULTS BDI (p < 0.001) and HADSA (p = 0.044) scores were significantly reduced at the 12-week follow-up. Significant improvements were found in Wechsler Adult Intelligence Scale (Third edition) immediate recall (p < 0.001) and delayed recall (p < 0.001) on the Rey-Osterrieth Complex Figure Test, and in delayed recall (p < 0.001), and immediate recall (p = 0.001) on the Logical Memory component of the Wechsler Memory Scale (Third Edition) at the 12-week follow-up. Participants completed the Stroop Inference Test significantly faster (p < 0.001); and required fewer number of attempts (p < 0.001) and produced fewer perseverative errors (p < 0.001) on the Wisconsin Card Sorting Test at the 12-week follow-up. CONCLUSION Chronic ketamine users' verbal and visual memory and executive functions improved after 12 weeks of ketamine abstinence.
Collapse
Affiliation(s)
- Wai Kwong Tang
- Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, China.
| | - Chieh Grace Lau
- Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, China
| | - Gabor S Ungvari
- Division of Psychiatry, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia; Section of Psychiatry, University Notre Dame Australia, Fremantle, Australia
| | - Shih-Ku Lin
- Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Psychiatry, Taipei City Hospital, Taipei, Taiwan
| | - Hsien-Yuan Lane
- Department of Psychiatry, China Medical University Hospital, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung, Taiwan
| |
Collapse
|
31
|
Dong M, Zeng LN, Zhang Q, Yang SY, Chen LY, Sim K, He YL, Chiu HFK, Sartorius N, Tan CH, Chong MY, Shinfuku N, Lin SK, Ng CH, Ungvari GS, Xiang YT. Antipsychotic Polypharmacy in Older Adult Asian Patients With Schizophrenia: Research on Asian Psychotropic Prescription Pattern. J Geriatr Psychiatry Neurol 2019; 32:304-311. [PMID: 31480982 DOI: 10.1177/0891988719862636] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND AND OBJECTIVE Antipsychotic polypharmacy (APP) is a controversial topic in the treatment of older adults with schizophrenia. The objective of this study was to examine the use of APP in older adult Asian patients with schizophrenia and its associated demographic and clinical factors. METHODS This study was based on the fourth survey of the consortium known as the Research on Asian Psychotropic Prescription Pattern for Antipsychotics. Fifteen Asian countries/territories participated in this survey, including Bangladesh, Mainland China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam. Basic demographic and clinical characteristics were collected using a standardized data collection form. RESULTS Among the 879 older adults with schizophrenia included in the survey, the rate of APP was 40.5%. Multiple logistic regression analysis revealed that higher antipsychotic doses (P < .001, odds ratio [OR] = 1.003, 95% confidence interval [CI]: 1.002-1.003), longer duration of illness (P = .02, OR = 1.845, 95% CI: 1.087-3.132), and the prescription of anticholinergics (P < .001, OR = 1.871, 95% CI: 1.329-2.635), second-generation antipsychotics (P = .001, OR = 2.264, 95% CI: 1.453-3.529), and first-generation antipsychotics (P < .001, OR = 3.344, 95% CI: 2.307-4.847) were significantly associated with APP. CONCLUSION Antipsychotic polypharmacy was common in older adult Asian patients with schizophrenia. Compared to the results of previous surveys, the use of APP showed a declining trend over time. Considering the general poor health status of older patients with schizophrenia and their increased risk of drug-induced adverse events, the use of APP in this population needs careful consideration.
Collapse
Affiliation(s)
- Min Dong
- 1 Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, & Center for Cognition and Brain Sciences, University of Macau, Macao SAR, China
| | - Liang-Nan Zeng
- 1 Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, & Center for Cognition and Brain Sciences, University of Macau, Macao SAR, China.,2 Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Sichuan Sheng, China
| | - Qinge Zhang
- 3 School of Mental Health, The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
| | - Shu-Yu Yang
- 4 Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan
| | - Lian-Yu Chen
- 5 Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Kang Sim
- 6 Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Yan-Ling He
- 7 Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
| | - Helen Fung-Kum Chiu
- 8 Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Norman Sartorius
- 9 Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
| | - Chay-Hoon Tan
- 10 Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- 11 Chiayi Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Chiayi, Taiwan
| | - Naotaka Shinfuku
- 12 International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan
| | - Shih-Ku Lin
- 13 Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chee H Ng
- 14 Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
| | - Gabor S Ungvari
- 15 University of Notre Dame Australia, Fremantle, Australia.,16 Division of Psychiatry, School of Medicine, University of Western Australia, Perth, Australia
| | - Yu-Tao Xiang
- 1 Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, & Center for Cognition and Brain Sciences, University of Macau, Macao SAR, China
| |
Collapse
|
32
|
Park SC, Oh HS, Tripathi A, Kallivayalil RA, Avasthi A, Grover S, Tanra AJ, Kanba S, Kato TA, Inada T, Chee KY, Chong MY, Lin SK, Sim K, Xiang YT, Tan CH, Javed A, Sartorius N, Shinfuku N, Park YC. Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia. Nord J Psychiatry 2019; 73:323-330. [PMID: 31240984 DOI: 10.1080/08039488.2019.1632381] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Background: Although cannabis use has been linked with schizophrenia in a dose-response pattern, to our knowledge, the relationship between cannabis and schizophrenia has rarely been reported in Asian population. Aim: We compared the clinical characteristics and psychotropic prescription patterns between cannabis users and non-users among Asian patients with schizophrenia. Moreover, we aimed to identify the independent correlates of cannabis use in these subjects. Methods: We performed the analysis of the data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), a collaborative consortium survey used to collate the prescription patterns for antipsychotic and other psychotropic medications in patients with schizophrenia in Asia. We included 132 schizophrenia patients in the group of lifetime cannabis use and 1756 in the group that had never used cannabis. A binary logistic model was fitted to detect the clinical correlates of lifetime cannabis use. Results: Adjusting for the effects of age, sex, geographical region, income group, duration of untreated psychosis, and Charlson comordity index level, a binary logistic regression model revealed that lifetime cannabis use was independently associated with aggressive behavior [adjusted odds ratio (aOR) = 1.582, 95% confidence interval (CI) = 1.006-2.490, p = .047] and with long-acting injectable antipsychotic treatment (aOR = 1.796, 95% CI = 1.444-2.820, p = .001). Conclusion: Our findings indicate a close link between lifetime cannabis use and aggressive behavior. The use of long-acting, injectable antipsychotics preferentially treats the aggressive behavior cannabis users among patients with schizophrenia in Asia, especially, the South or Southeast Asia.
Collapse
Affiliation(s)
- Seon-Cheol Park
- a Department of Psychiatry, Inje Universtiy Haeundae Paik Hospital , Busan , Republic of Korea
| | - Hong Seok Oh
- b Department of Psychiatry, Konyang University Hospital , Daejeon , Republic of Korea
| | - Adarsh Tripathi
- c Department of Psychiatry, King George's Medical University , Chowk , India
| | | | - Ajit Avasthi
- e Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India
| | - Sandeep Grover
- e Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India
| | - Andi Jayalangkara Tanra
- f Faculty of Medicine, Department of Psychiatry, Hasanuddin University , Makassar , Indonesia
| | - Shigenobu Kanba
- g Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University , Fukuoka , Japan
| | - Takahiro A Kato
- g Department of Neuropsychiatry, Graduate School of Medicine, Kyushu University , Fukuoka , Japan
| | - Toshiya Inada
- h Department of Psychiatry and Psychobiology, Nagoya University, Graduate School of Medicine , Nagoya , Japan
| | - Kok Yoon Chee
- i Tunku Abdul Rahman Institute of Neuroscience, Kuala Lumpur Hospital , Kuala Lumpur , Malaysia
| | - Mian-Yoon Chong
- j Chang Gung Memorial Hospital , Chiayi , Taiwan.,k Chang Gung University School of Medicine , Taoyuan City , Taiwan
| | - Shih-Ku Lin
- l Psychiatric Center, Taipei City Hospital , Taipei , Taiwan
| | - Kang Sim
- m West Region, Institute of Mental Health and Yong Loo Lin School of Medicine, National University of Singapore , Singapore , Singapore
| | - Yu-Tao Xiang
- n Faculty of Health Sciences, Unit of Psychiatry, Institute of Translational Medicine, University of Macau , Macau SAR , China
| | - Chay Hoon Tan
- o Department of Pharmacology, National University Hospital , Singapore , Singapore
| | - Afzal Javed
- p Pakistan Psychiatric Research Centre, Fountain House , Lahore , Pakistan
| | - Norman Sartorius
- q Association for the Improvement of Mental Health Programmes , Geneva , Switzerland
| | - Naotaka Shinfuku
- r Department of Social Welfare, School of Human Sciences, Seinan Gakuin University , Fukuoka , Japan
| | - Yong Chon Park
- s Department of Neuropsychiatry, Hanyang University Guri Hospital , Guri , Republic of Korea
| |
Collapse
|
33
|
Park SC, Kim K, Jang OJ, Kim SG, Lee JG, Park JH, Choi J, Lee DW, Lin SK, Tan CH, Shinfuku N, Park YC. Clinical Characteristics and Psychotropic Drug Prescription Patterns of Bipolar Disorder Patients with a History of Suicidal Attempts: Findings from the REAP-BD, Korea. Psychiatry Investig 2019; 16:459-463. [PMID: 31247705 PMCID: PMC6603704 DOI: 10.30773/pi.2019.03.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 03/10/2019] [Indexed: 12/16/2022] Open
Abstract
Our study aimed to analyze the clinical characteristics and psychotropic prescription patterns of a history of suicide attempts in South Koreans with bipolar disorder (BD), by using only Korean data from the Research on Asian Psychotropic Prescription Pattern for Bipolar disorder. The patterns of clinical characteristics and psychotropic drug use were compared among 53 patients with a history of suicide attempts and 297 without this history; the potential effects of confounding variables were adjusted with binary logistic analyses for discrete variables and analyses of covariance for continuous variables. After adjusting the effects of age, sex, duration of illness, and enrollment as an outpatient, patients with a history of suicide attempts were characterized by a significantly more prevalent depressive episode, lower prevalent remission state, lower levels of hemoglobin, and more use of antidepressants, anxiolytics, and hypnotics compared to those without lifetime suicide attempt. The inability to plan goal-directed behavior may be an intervening factor in the relationship between suicide attempts and depression in BD. Relatively low hemoglobin levels can be associated with manic episodes in patients with a history of suicide attempts and the use of antidepressants, anxiolytics, or hypnotics can be associated with suicide attempts in BD patients.
Collapse
Affiliation(s)
- Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Kiwon Kim
- Department of Psychiatry, Veteran Health Service Medical Center, Seoul, Republic of Korea
| | - Ok-Jin Jang
- Department of Psychiatry, Bugok National Hospital, Changyeong, Republic of Korea
| | - Seung-Gon Kim
- Department of Psychiatry, Chosun University Hosptial, Gwangju, Republic of Korea
| | - Jung Goo Lee
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Joon Hyuk Park
- Department of Psychiatry, Jeju National University, Jeju, Republic of Korea
| | - Joonho Choi
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Dong-Woo Lee
- Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea
| | - Shih-Ku Lin
- Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Chay Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore, Singapore
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| |
Collapse
|
34
|
Kim K, Yang H, Na E, Lee H, Jang OJ, Yoon HJ, Oh HS, Ham BJ, Park SC, Lin SK, Tan CH, Shinfuku N, Park YC. Examining Patterns of Polypharmacy in Bipolar Disorder: Findings from the REAP-BD, Korea. Psychiatry Investig 2019; 16:397-402. [PMID: 31132844 PMCID: PMC6539270 DOI: 10.30773/pi.2019.02.26.4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 02/14/2019] [Accepted: 02/26/2019] [Indexed: 12/15/2022] Open
Abstract
Based on Korean data from the Research on Asian Psychotropic Prescription Pattern for Bipolar Disorder, this study tried to present prescription patterns in biopolar disorder (BD) and its associated clinical features. Based on the information obtained from the study with structured questions, the tendency of prescription pattern was studied and analyzed. Polypharmacy was predominant, including simple polypharmacy in 51.1% and complex polypharmacy in 34.2% of patients. Subjects associated with simple or complex polypharmacy were significantly younger, had higher inpatient settings, a larger portion of onset with manic episode, a shorter duration of untreated illness, a shorter duration of current episode, were more overweight, used less antidepressants and used more anxiolytics. These findings can suggest higher polypharmacy rate in more severe BD and highlight the necessity of monitoring the weight of subjects with polypharmacy.
Collapse
Affiliation(s)
- Kiwon Kim
- Department of Psychiatry, Veteran Health Service Medical Center, Seoul, Republic of Korea
| | - Hyunju Yang
- Department of Psychiatry, Jeju National University, Jeju, Republic of Korea
| | - Euihyeon Na
- Department of Psychiatry, Incheon Chamsarang Hospital, Incheon, Republic of Korea
| | - Hoseon Lee
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Ok-Jin Jang
- Department of Psychiatry, Bugok National Hospital, Changyeong, Republic of Korea
| | - Hyung-Jun Yoon
- Department of Psychiatry, Chosun University Hosptial, Gwangju, Republic of Korea
| | - Hong Seok Oh
- Department of Psychiatry, Konyang University Hospital, Daejeon, Republic of Korea
| | - Byung-Joo Ham
- Department of Psychiatry, Korea University Anam Hospital, Seoul, Republic of Korea
| | - Seon-Cheol Park
- Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, Republic of Korea
| | - Shih-Ku Lin
- Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
| | - Chay Hoon Tan
- Department of Pharmacology, National University Hospital, Singapore, Singapore
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Yong Chon Park
- Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
| |
Collapse
|
35
|
Chen W, Lai YC, Lin SK, Huang MC, Liu HC, Chiou YL, Chen CH. Relations of genetic variants in superoxide dismutase 2 and dystrobrevin-binding protein 1 to methamphetamine psychosis among methamphetamine dependents in Taiwan. Taiwan J Psychiatry 2019. [DOI: 10.4103/tpsy.tpsy_23_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
36
|
Adey D, An FP, Balantekin AB, Band HR, Bishai M, Blyth S, Cao D, Cao GF, Cao J, Chan YL, Chang JF, Chang Y, Chen HS, Chen SM, Chen Y, Chen YX, Cheng J, Cheng ZK, Cherwinka JJ, Chu MC, Chukanov A, Cummings JP, Deng FS, Ding YY, Diwan MV, Dolgareva M, Dwyer DA, Edwards WR, Gonchar M, Gong GH, Gong H, Gu WQ, Guo L, Guo XH, Guo YH, Guo Z, Hackenburg RW, Hans S, He M, Heeger KM, Heng YK, Higuera A, Hsiung YB, Hu BZ, Hu JR, Hu T, Hu ZJ, Huang HX, Huang XT, Huang YB, Huber P, Huo W, Hussain G, Jaffe DE, Jen KL, Ji XL, Ji XP, Johnson RA, Jones D, Kang L, Kettell SH, Koerner LW, Kohn S, Kramer M, Langford TJ, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li F, Li HL, Li QJ, Li S, Li SC, Li SJ, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu JC, Liu JL, Liu Y, Liu YH, Loh CW, Lu C, Lu HQ, Lu JS, Luk KB, Ma XB, Ma XY, Ma YQ, Malyshkin Y, Marshall C, Martinez Caicedo DA, McDonald KT, McKeown RD, Mitchell I, Mora Lepin L, Napolitano J, Naumov D, Naumova E, Ochoa-Ricoux JP, Olshevskiy A, Pan HR, Park J, Patton S, Pec V, Peng JC, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Qiu RM, Raper N, Ren J, Rosero R, Roskovec B, Ruan XC, Steiner H, Sun JL, Tang W, Taychenachev D, Treskov K, Tse WH, Tull CE, Viren B, Vorobel V, Wang CH, Wang J, Wang M, Wang NY, Wang RG, Wang W, Wang W, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Wei HY, Wei LH, Wen LJ, Whisnant K, White CG, Wise T, Wong HLH, Wong SCF, Worcester E, Wu Q, Wu WJ, Xia DM, Xing ZZ, Xu JL, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Yang YZ, Ye M, Yeh M, Young BL, Yu HZ, Yu ZY, Yue BB, Zeng S, Zhan L, Zhang C, Zhang CC, Zhang FY, Zhang HH, Zhang JW, Zhang QM, Zhang R, Zhang XF, Zhang XT, Zhang YM, Zhang YM, Zhang YX, Zhang YY, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zheng P, Zhou L, Zhuang HL, Zou JH. Measurement of the Electron Antineutrino Oscillation with 1958 Days of Operation at Daya Bay. Phys Rev Lett 2018; 121:241805. [PMID: 30608728 DOI: 10.1103/physrevlett.121.241805] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Indexed: 06/09/2023]
Abstract
We report a measurement of electron antineutrino oscillation from the Daya Bay Reactor Neutrino Experiment with nearly 4 million reactor ν[over ¯]_{e} inverse β decay candidates observed over 1958 days of data collection. The installation of a flash analog-to-digital converter readout system and a special calibration campaign using different source enclosures reduce uncertainties in the absolute energy calibration to less than 0.5% for visible energies larger than 2 MeV. The uncertainty in the cosmogenic ^{9}Li and ^{8}He background is reduced from 45% to 30% in the near detectors. A detailed investigation of the spent nuclear fuel history improves its uncertainty from 100% to 30%. Analysis of the relative ν[over ¯]_{e} rates and energy spectra among detectors yields sin^{2}2θ_{13}=0.0856±0.0029 and Δm_{32}^{2}=(2.471_{-0.070}^{+0.068})×10^{-3} eV^{2} assuming the normal hierarchy, and Δm_{32}^{2}=-(2.575_{-0.070}^{+0.068})×10^{-3} eV^{2} assuming the inverted hierarchy.
Collapse
Affiliation(s)
- D Adey
- Institute of High Energy Physics, Beijing
| | - F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | | | - H R Band
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
- National United University, Miao-Li
| | - D Cao
- Nanjing University, Nanjing
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - Y Chang
- National United University, Miao-Li
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
| | - Y X Chen
- North China Electric Power University, Beijing
| | | | - Z K Cheng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | | | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | - A Chukanov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | | | - F S Deng
- University of Science and Technology of China, Hefei
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973
| | - M Dolgareva
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - W Q Gu
- Brookhaven National Laboratory, Upton, New York 11973
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | - Y H Guo
- Department of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an
| | - Z Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | | | - S Hans
- Brookhaven National Laboratory, Upton, New York 11973
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas 77204
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei
| | - J R Hu
- Institute of High Energy Physics, Beijing
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - Z J Hu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | | | - Y B Huang
- Institute of High Energy Physics, Beijing
| | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - W Huo
- University of Science and Technology of China, Hefei
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | - X P Ji
- Brookhaven National Laboratory, Upton, New York 11973
| | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221
| | - D Jones
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York 11973
| | - L W Koerner
- Department of Physics, University of Houston, Houston, Texas 77204
| | - S Kohn
- Department of Physics, University of California, Berkeley, California 94720
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - T J Langford
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J H C Lee
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C Li
- Shandong University, Jinan
| | - F Li
- Institute of High Energy Physics, Beijing
| | - H L Li
- Shandong University, Jinan
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - S Li
- Dongguan University of Technology, Dongguan
| | - S C Li
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - S J Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - X Q Li
- School of Physics, Nankai University, Tianjin
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Lin
- Dongguan University of Technology, Dongguan
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas 77204
| | - Y-C Lin
- Department of Physics, National Taiwan University, Taipei
| | - J J Ling
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York 11973
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | - J L Liu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Y Liu
- Shandong University, Jinan
| | | | | | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - J S Lu
- Institute of High Energy Physics, Beijing
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - X B Ma
- North China Electric Power University, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - Y Malyshkin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - C Marshall
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - D A Martinez Caicedo
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544
| | - R D McKeown
- California Institute of Technology, Pasadena, California 91125
- College of William and Mary, Williamsburg, Virginia 23187
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas 77204
| | - L Mora Lepin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J P Ochoa-Ricoux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas 77204
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York 11973
| | - R M Qiu
- North China Electric Power University, Beijing
| | - N Raper
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York 11973
| | - B Roskovec
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - J L Sun
- China General Nuclear Power Group, Shenzhen
| | - W Tang
- Brookhaven National Laboratory, Upton, New York 11973
| | - D Taychenachev
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K Treskov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - W-H Tse
- Chinese University of Hong Kong, Hong Kong
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague
| | - C H Wang
- National United University, Miao-Li
| | - J Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- College of William and Mary, Williamsburg, Virginia 23187
| | - W Wang
- Nanjing University, Nanjing
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - H Y Wei
- Brookhaven National Laboratory, Upton, New York 11973
| | - L H Wei
- Institute of High Energy Physics, Beijing
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | | | - C G White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616
| | - T Wise
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - S C F Wong
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York 11973
| | - Q Wu
- Shandong University, Jinan
| | - W J Wu
- Institute of High Energy Physics, Beijing
| | - D M Xia
- Chongqing University, Chongqing
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - H Yang
- Nanjing University, Nanjing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | | | - Y Z Yang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - M Ye
- Institute of High Energy Physics, Beijing
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York 11973
| | - B L Young
- Iowa State University, Ames, Iowa 50011
| | - H Z Yu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | - B B Yue
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - S Zeng
- Institute of High Energy Physics, Beijing
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York 11973
| | - C C Zhang
- Institute of High Energy Physics, Beijing
| | - F Y Zhang
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | - Q M Zhang
- Department of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an
| | | | - X F Zhang
- Institute of High Energy Physics, Beijing
| | - X T Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Y M Zhang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y X Zhang
- China General Nuclear Power Group, Shenzhen
| | - Y Y Zhang
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - P Zheng
- Dongguan University of Technology, Dongguan
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
37
|
Chen PY, Chen CH, Chang CK, Kao CF, Lu ML, Lin SK, Huang MC, Hwang LL, Mondelli V. Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. Int J Neuropsychopharmacol 2018; 22:28-36. [PMID: 30204875 PMCID: PMC6313111 DOI: 10.1093/ijnp/pyy075] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 09/01/2018] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The role of orexin-A in regulating metabolic homeostasis has been recognized, but its association with antipsychotic-induced metabolic abnormalities remains unclear. We investigated the association between orexin-A levels and metabolic syndrome in patients with schizophrenia treated with clozapine or less obesogenic antipsychotics compared with nonpsychiatric controls. METHODS Plasma orexin-A levels and metabolic parameters were determined in 159 patients with schizophrenia: 109 taking clozapine; 50 taking aripiprazole, amisulpride, ziprasidone, or haloperidol; and 60 nonpsychiatric controls. RESULTS Orexin-A levels were significantly higher in the group taking less obesogenic antipsychotics, followed by the clozapine group and the controls (F=104.6, P<.01). Higher orexin-A levels were correlated with better metabolic profiles in the patient groups but not in the controls. Regression analyses revealed that the patients with higher orexin-A levels had significantly lower risk of metabolic syndrome (adjusted odds ratio [OR]=0.04, 95% CI: 0.01-0.38 for the 2nd tertile; OR=0.04, 95% CI: 0.01-0.36 for the 3rd tertile, compared with the first tertile), after adjustment for age, sex, smoking history, types of antipsychotics (clozapine vs less obesogenic antipsychotics), duration of antipsychotic treatment, and disease severity. CONCLUSIONS Our results revealed that the orexin-A level was upregulated in patients with schizophrenia treated with antipsychotics, especially for the group taking less obesogenic antipsychotics. Furthermore, higher orexin-A levels were independently associated with better metabolic profiles. These observations suggest that an upregulation of orexin-A has a protective effect against the development of metabolic abnormalities in patients with schizophrenia receiving antipsychotic treatment.
Collapse
Affiliation(s)
- Po-Yu Chen
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan,Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan,Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Chun-Hsin Chen
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan,Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Chin-Kuo Chang
- Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,Department of Health and Welfare, University of Taipei, Taipei, Taiwan
| | - Chung-Feng Kao
- Department of Agronomy, College of Agriculture & Natural Resources, National Chung-Hsing University, Taichung, Taiwan
| | - Mong-Liang Lu
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan,Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan
| | - Ming-Chyi Huang
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan,Psychiatric Research Center, Taipei Medical University Hospital,Correspondence: Ming-Chyi Huang, MD, PhD, Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, 309 Song-de Road, Taipei 110, Taiwan (); and Ling-Ling Hwang, PhD, Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei 110, Taiwan ()
| | - Ling-Ling Hwang
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan,Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan,Correspondence: Ming-Chyi Huang, MD, PhD, Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, 309 Song-de Road, Taipei 110, Taiwan (); and Ling-Ling Hwang, PhD, Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei 110, Taiwan ()
| | - Valeria Mondelli
- Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| |
Collapse
|
38
|
Yang SY, Chen LY, Najoan E, Kallivayalil RA, Viboonma K, Jamaluddin R, Javed A, Hoa DTQ, Iida H, Sim K, Swe T, He YL, Park Y, Ahmed HU, De Alwis A, Chiu HFK, Sartorius N, Tan CH, Chong MY, Shinfuku N, Lin SK. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry Clin Neurosci 2018; 72:572-579. [PMID: 29761577 DOI: 10.1111/pcn.12676] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 12/28/2017] [Accepted: 01/30/2018] [Indexed: 11/28/2022]
Abstract
AIM The aim of the present study was to survey the prevalence of antipsychotic polypharmacy and combined medication use across 15 Asian countries and areas in 2016. METHODS By using the results from the fourth survey of Research on Asian Prescription Patterns on antipsychotics, the rates of polypharmacy and combined medication use in each country were analyzed. Daily medications prescribed for the treatment of inpatients or outpatients with schizophrenia, including antipsychotics, mood stabilizers, anxiolytics, hypnotics, and antiparkinson agents, were collected. Fifteen countries from Asia participated in this study. RESULTS A total of 3744 patients' prescription forms were examined. The prescription patterns differed across these Asian countries, with the highest rate of polypharmacy noted in Vietnam (59.1%) and the lowest in Myanmar (22.0%). Furthermore, the combined use of other medications, expressed as highest and lowest rate, respectively, was as follows: mood stabilizers, China (35.0%) and Bangladesh (1.0%); antidepressants, South Korea (36.6%) and Bangladesh (0%); anxiolytics, Pakistan (55.7%) and Myanmar (8.5%); hypnotics, Japan (61.1%) and, equally, Myanmar (0%) and Sri Lanka (0%); and antiparkinson agents, Bangladesh (87.9%) and Vietnam (10.9%). The average psychotropic drug loading of all patients was 2.01 ± 1.64, with the highest and lowest loadings noted in Japan (4.13 ± 3.13) and Indonesia (1.16 ± 0.68), respectively. CONCLUSION Differences in psychiatrist training as well as the civil culture and health insurance system of each country may have contributed to the differences in these rates. The concept of drug loading can be applied to other medical fields.
Collapse
Affiliation(s)
- Shu-Yu Yang
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Lian-Yu Chen
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
| | - Eunice Najoan
- Dr Mintohardjo Indonesian Navy Hospital, Jakarta, Indonesia
| | | | | | - Ruzita Jamaluddin
- Department of Psychiatry & Mental Health, Hospital Tuanku Fauziah, Kangar, Malaysia
| | - Afzal Javed
- Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
| | | | - Hitoshi Iida
- Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Kang Sim
- Department of General Psychiatry, Institute of Mental Health, Buangkok Green Medical Park, Singapore
| | - Thiha Swe
- Department of Mental Health, University of Medicine, Magway, Myanmar
| | - Yan-Ling He
- Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
| | - Yongchon Park
- Department of Psychiatry, Hanyang University, Seoul, Korea
| | - Helal Uddin Ahmed
- Department of Child Adolescent and Family Psychiatry, National Institute of Mental Health, Dhaka, Bangladesh
| | | | - Helen Fung-Kum Chiu
- Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Norman Sartorius
- Association for the Improvement of Mental Health Programs, Geneva, Switzerland
| | - Chay-Hoon Tan
- Department of Pharmacology, National University of Singapore, Singapore
| | - Mian-Yoon Chong
- Department of General Psychiatry, Chiayi Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Chiayi, Taiwan
| | - Naotaka Shinfuku
- Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|
39
|
Wang LJ, Chen CK, Lin SK, Chen YC, Xu K, Huang MC. Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls. Psychopharmacology (Berl) 2018; 235:2113-2121. [PMID: 29713787 DOI: 10.1007/s00213-018-4910-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 04/17/2018] [Indexed: 01/22/2023]
Abstract
BACKGROUND Ketamine has emerged as a major substance of abuse worldwide and has been listed with methamphetamine (METH) as two of the most widely available illicit substances in Taiwan. Only a few studies have examined the long-term consequences of chronic and heavy ketamine abuse. We compared the cognitive function of ketamine-dependent patients with that of METH-dependent patients and healthy controls. METHODS We recruited 165 participants (58 ketamine-dependent and 49 METH-dependent patients who sought treatment and 58 healthy controls) and evaluated them by using a cognitive test battery, the Brief Assessment of Cognition in Schizophrenia, with scores being estimated in reference to normative data in general population. RESULTS The ketamine-dependent patients had significantly poorer performance than did the controls in many cognitive tests, including verbal memory, motor speed, verbal fluency, and attention and processing speed, and the battery as a whole. METH-dependent patients exhibited poorer function in motor speed, verbal fluency, and attention and processing speed. The ketamine group performed poorer than did METH group in the domains of verbal memory, working memory, and attention and processing speed and the composite battery scores. A previous experience of ketamine-induced psychotomimetic symptoms, using higher doses of ketamine, and longer abstinence appeared to be associated with performance in some tests; however, the significance disappeared after multiple comparison correction. CONCLUSIONS The ketamine-dependent patients had impaired cognitive function, and METH-dependent patients exhibited intermediate performance between ketamine-dependent patients and healthy controls. Given the growing population of ketamine abusers, public education on the cognitive consequences should be provided.
Collapse
Affiliation(s)
- Liang-Jen Wang
- Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.,Department of Psychiatry, Chang Gung Memorial Hospital, Keelung, Taiwan
| | - Chih-Ken Chen
- Department of Psychiatry, Chang Gung Memorial Hospital, Keelung, Taiwan.,Chang Gung University School of Medicine, Taoyuan, Taiwan
| | - Shih-Ku Lin
- Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, 309, Song-De Road, Taipei, Taiwan
| | - Yi-Chih Chen
- Department of Psychiatry, Chang Gung Memorial Hospital, Keelung, Taiwan.,Chang Gung University School of Medicine, Taoyuan, Taiwan
| | - Ke Xu
- Department of Psychiatry, Yale School of Medicine, New Heaven, CT, USA
| | - Ming-Chyi Huang
- Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan. .,Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, 309, Song-De Road, Taipei, Taiwan.
| |
Collapse
|
40
|
Rice TR, Shah LD, Trelles P, Lin SK, Christensen DS, Walther A, Sher L. Mental health of the male adolescent and young man: the Copenhagen statement. World J Pediatr 2018; 14:224-232. [PMID: 29679360 DOI: 10.1007/s12519-018-0155-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Revised: 03/20/2018] [Accepted: 03/27/2018] [Indexed: 12/17/2022]
Abstract
BACKGROUND Male adolescents and young men benefit when their mental health care is specialized to match their unique gendered and developmental needs. Sensitivity to the social circumstances of this population is important; additionally, the emerging ability to tailor care through knowledge gleaned from the intersection of psychiatry, neurology, and endocrinology informs care. DATA SOURCES This article summarized the views of six experts in the area of the adolescent and young adult male mental health. These experts were select members of the World Federation of Societies of Biological Psychiatry's Task Force on Men's Mental Health. They convened to present two symposia on the topic of men's mental health at the 13th World Congress of Biological Psychiatry (WCBP) in Copenhagen, Denmark in 2017. RESULTS In these works, a special focus is paid to addictive disorders, disruptive behavior disorders, aggression, and brain development. Collectively, the authors present an argument for the merits of a male-specific model of mental health care to advance the overall well-being of this population. CONCLUSIONS Men's mental health should be recognized as a social issue as much as a medical issue, with special attention paid to problems such as unemployment, familial disruption, and substance abuse. These problems, and especially those of major societal impact including violence and suicide which are much more frequently the product of male youth and men, should have more male-tailored options for service provision that respond to men's mental health needs.
Collapse
Affiliation(s)
- Timothy R Rice
- Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA.
| | - Lesha D Shah
- New York University School of Medicine, New York, NY, USA
| | - Pilar Trelles
- Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA
| | - Shih-Ku Lin
- Taipei City Hospital and Taipei Medical University, Taipei, China
| | - Dinne Skjærlund Christensen
- Department of Public Health, Center for Healthy Aging and Section of Environmental Health, University of Copenhagen, Copenhagen, Denmark
| | - Andreas Walther
- Biological Psychology, TU Dresden, Dresden, Germany
- Clinical Psychology and Psychotherapy, University of Zurich, Zurich, Switzerland
| | - Leo Sher
- James J. Peters VA Medical Center and Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
41
|
Hung YN, Yang SY, Kuo CJ, Lin SK. Diagnostic consistency and interchangeability of schizophrenic disorders and bipolar disorders: A 7-year follow-up study. Psychiatry Clin Neurosci 2018; 72:180-188. [PMID: 29265573 DOI: 10.1111/pcn.12629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 12/07/2017] [Accepted: 12/11/2017] [Indexed: 11/27/2022]
Abstract
AIM The change in psychiatric diagnoses in clinical practice is not an unusual phenomenon. The interchange between the diagnoses of schizophrenic disorders and bipolar disorders is a major clinical issue because of the differences in treatment regimens and long-term prognoses. In this study, we used a nationwide population-based sample to compare the diagnostic consistency and interchange rate between schizophrenic disorders and bipolar disorders. METHODS In total, 25 711 and 11 261 patients newly diagnosed as having schizophrenic disorder and bipolar disorder, respectively, were retrospectively enrolled from the Psychiatric Inpatient Medical Claims database between 2001 and 2005. We followed these two cohorts for 7 years to determine whether their diagnoses were consistent throughout subsequent hospitalizations. The interchange between the two diagnoses was analyzed. RESULTS In the schizophrenic disorder cohort, the overall diagnostic consistency rate was 87.3% and the rate of change to bipolar disorder was 3.0% during the 7-year follow-up. Additional analyses of subtypes revealed that the change rate from schizoaffective disorder to bipolar disorder was 12.0%. In the bipolar disorder cohort, the overall diagnostic consistency rate was 71.9% and the rate of change to schizophrenic disorder was 8.3%. CONCLUSION Changes in the diagnosis of a major psychosis are not uncommon. The interchange between the diagnoses of schizophrenic disorders and bipolar disorders might be attributed to the evolution of clinical symptoms and the observation of preserved social functions that contradict the original diagnosis. While making a psychotic diagnosis, clinicians should be aware of the possibility of the change in diagnosis in the future.
Collapse
Affiliation(s)
- Yen-Ni Hung
- School of Gerontology Health Management, College of Nursing, Taipei Medical University, Taipei, Taiwan.,Department of Nursing, School of Nursing, National Yang-Ming University, Taipei, Taiwan
| | - Shu-Yu Yang
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.,Graduate Institute of Clinical Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Chian-Jue Kuo
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.,Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.,Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|
42
|
Chiu CC, Lu ML, Huang MC, Chen PY, Lin YK, Lin SK, Chen CH. Correction: Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. PLoS One 2018; 13:e0193315. [PMID: 29451914 PMCID: PMC5815597 DOI: 10.1371/journal.pone.0193315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
43
|
Huang MC, Lai YC, Lin SK, Chen CH. Increased blood 8-hydroxy-2-deoxyguanosine levels in methamphetamine users during early abstinence. The American Journal of Drug and Alcohol Abuse 2017; 44:395-402. [DOI: 10.1080/00952990.2017.1344683] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Ming-Chyi Huang
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Ying-Ching Lai
- Department of Psychiatry, Cathay General Hospital, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chun-Hsin Chen
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|
44
|
An FP, Balantekin AB, Band HR, Bishai M, Blyth S, Cao D, Cao GF, Cao J, Chan YL, Chang JF, Chang Y, Chen HS, Chen QY, Chen SM, Chen YX, Chen Y, Cheng J, Cheng ZK, Cherwinka JJ, Chu MC, Chukanov A, Cummings JP, Ding YY, Diwan MV, Dolgareva M, Dove J, Dwyer DA, Edwards WR, Gill R, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guo L, Guo XH, Guo YH, Guo Z, Hackenburg RW, Hans S, He M, Heeger KM, Heng YK, Higuera A, Hsiung YB, Hu BZ, Hu T, Huang EC, Huang HX, Huang XT, Huang YB, Huber P, Huo W, Hussain G, Jaffe DE, Jen KL, Ji XP, Ji XL, Jiao JB, Johnson RA, Jones D, Kang L, Kettell SH, Khan A, Kohn S, Kramer M, Kwan KK, Kwok MW, Langford TJ, Lau K, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li DJ, Li F, Li GS, Li QJ, Li S, Li SC, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu JL, Liu JC, Loh CW, Lu C, Lu HQ, Lu JS, Luk KB, Ma XY, Ma XB, Ma YQ, Malyshkin Y, Martinez Caicedo DA, McDonald KT, McKeown RD, Mitchell I, Nakajima Y, Napolitano J, Naumov D, Naumova E, Ngai HY, Ochoa-Ricoux JP, Olshevskiy A, Pan HR, Park J, Patton S, Pec V, Peng JC, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Qiu RM, Raper N, Ren J, Rosero R, Roskovec B, Ruan XC, Steiner H, Stoler P, Sun JL, Tang W, Taychenachev D, Treskov K, Tsang KV, Tull CE, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Wei HY, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu CH, Wu Q, Wu WJ, Xia DM, Xia JK, Xing ZZ, Xu JL, Xu Y, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Yang YZ, Ye M, Ye Z, Yeh M, Young BL, Yu ZY, Zeng S, Zhan L, Zhang C, Zhang CC, Zhang HH, Zhang JW, Zhang QM, Zhang R, Zhang XT, Zhang YM, Zhang YX, Zhang YM, Zhang ZJ, Zhang ZY, Zhang ZP, Zhao J, Zhou L, Zhuang HL, Zou JH. Evolution of the Reactor Antineutrino Flux and Spectrum at Daya Bay. Phys Rev Lett 2017; 118:251801. [PMID: 28696753 DOI: 10.1103/physrevlett.118.251801] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Indexed: 06/07/2023]
Abstract
The Daya Bay experiment has observed correlations between reactor core fuel evolution and changes in the reactor antineutrino flux and energy spectrum. Four antineutrino detectors in two experimental halls were used to identify 2.2 million inverse beta decays (IBDs) over 1230 days spanning multiple fuel cycles for each of six 2.9 GW_{th} reactor cores at the Daya Bay and Ling Ao nuclear power plants. Using detector data spanning effective ^{239}Pu fission fractions F_{239} from 0.25 to 0.35, Daya Bay measures an average IBD yield σ[over ¯]_{f} of (5.90±0.13)×10^{-43} cm^{2}/fission and a fuel-dependent variation in the IBD yield, dσ_{f}/dF_{239}, of (-1.86±0.18)×10^{-43} cm^{2}/fission. This observation rejects the hypothesis of a constant antineutrino flux as a function of the ^{239}Pu fission fraction at 10 standard deviations. The variation in IBD yield is found to be energy dependent, rejecting the hypothesis of a constant antineutrino energy spectrum at 5.1 standard deviations. While measurements of the evolution in the IBD spectrum show general agreement with predictions from recent reactor models, the measured evolution in total IBD yield disagrees with recent predictions at 3.1σ. This discrepancy indicates that an overall deficit in the measured flux with respect to predictions does not result from equal fractional deficits from the primary fission isotopes ^{235}U, ^{239}Pu, ^{238}U, and ^{241}Pu. Based on measured IBD yield variations, yields of (6.17±0.17) and (4.27±0.26)×10^{-43} cm^{2}/fission have been determined for the two dominant fission parent isotopes ^{235}U and ^{239}Pu. A 7.8% discrepancy between the observed and predicted ^{235}U yields suggests that this isotope may be the primary contributor to the reactor antineutrino anomaly.
Collapse
Affiliation(s)
- F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | | | - H R Band
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
- National United University, Miao-Li
| | - D Cao
- Nanjing University, Nanjing
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - Y Chang
- National United University, Miao-Li
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | | | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y X Chen
- North China Electric Power University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
| | | | - Z K Cheng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | | | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | - A Chukanov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | | | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973
| | - M Dolgareva
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J Dove
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - R Gill
- Brookhaven National Laboratory, Upton, New York 11973
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - M Grassi
- Institute of High Energy Physics, Beijing
| | - W Q Gu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | - Y H Guo
- Department of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an
| | - Z Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | | | - S Hans
- Brookhaven National Laboratory, Upton, New York 11973
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas 77204
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | | | - Y B Huang
- Institute of High Energy Physics, Beijing
| | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - W Huo
- University of Science and Technology of China, Hefei
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - X P Ji
- Department of Engineering Physics, Tsinghua University, Beijing
- School of Physics, Nankai University, Tianjin
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | | | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221
| | - D Jones
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York 11973
| | - A Khan
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - S Kohn
- Department of Physics, University of California, Berkeley, California 94720
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong
| | - T J Langford
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas 77204
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J H C Lee
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C Li
- Shandong University, Jinan
| | - D J Li
- University of Science and Technology of China, Hefei
| | - F Li
- Institute of High Energy Physics, Beijing
| | - G S Li
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - S Li
- Dongguan University of Technology, Dongguan
| | - S C Li
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - X Q Li
- School of Physics, Nankai University, Tianjin
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Lin
- Dongguan University of Technology, Dongguan
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas 77204
| | - Y-C Lin
- Department of Physics, National Taiwan University, Taipei
| | - J J Ling
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York 11973
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616
| | - J L Liu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | | | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - J S Lu
- Institute of High Energy Physics, Beijing
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - X B Ma
- North China Electric Power University, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - Y Malyshkin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - D A Martinez Caicedo
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544
| | - R D McKeown
- California Institute of Technology, Pasadena, California 91125
- College of William and Mary, Williamsburg, Virginia 23187
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas 77204
| | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - J P Ochoa-Ricoux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas 77204
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York 11973
| | - R M Qiu
- North China Electric Power University, Beijing
| | - N Raper
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York 11973
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - P Stoler
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180
| | - J L Sun
- China General Nuclear Power Group, Shenzhen
| | - W Tang
- Brookhaven National Laboratory, Upton, New York 11973
| | - D Taychenachev
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K Treskov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - N Viaux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague
| | - C H Wang
- National United University, Miao-Li
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- College of William and Mary, Williamsburg, Virginia 23187
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - H Y Wei
- Department of Engineering Physics, Tsinghua University, Beijing
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | | | - C G White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas 77204
| | - T Wise
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
- Department of Physics, University of California, Berkeley, California 94720
| | - S C F Wong
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York 11973
| | - C-H Wu
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Q Wu
- Shandong University, Jinan
| | - W J Wu
- Institute of High Energy Physics, Beijing
| | - D M Xia
- Chongqing University, Chongqing
| | - J K Xia
- Institute of High Energy Physics, Beijing
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - Y Xu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - H Yang
- Nanjing University, Nanjing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | | | - Y Z Yang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - M Ye
- Institute of High Energy Physics, Beijing
| | - Z Ye
- Department of Physics, University of Houston, Houston, Texas 77204
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York 11973
| | - B L Young
- Iowa State University, Ames, Iowa 50011
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | - S Zeng
- Institute of High Energy Physics, Beijing
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York 11973
| | - C C Zhang
- Institute of High Energy Physics, Beijing
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | - Q M Zhang
- Department of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an
| | | | - X T Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y X Zhang
- China General Nuclear Power Group, Shenzhen
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
45
|
Chiu CC, Lu ML, Huang MC, Chen PY, Lin YK, Lin SK, Chen CH. Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. PLoS One 2016; 11:e0168347. [PMID: 27973619 PMCID: PMC5156367 DOI: 10.1371/journal.pone.0168347] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Accepted: 11/20/2016] [Indexed: 11/18/2022] Open
Abstract
Background Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. The lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d. This study was designed to determine whether metformin at 500 mg/d and 1000 mg/d is effective in improving the metabolic profiles of clozapine-treated patients with pre-existing metabolic abnormalities, and whether its effectiveness depends on metformin dosage. Methods In this 12-week, randomized, double-blind, placebo-controlled trial, metformin at 500 mg/d or 1000 mg/d was prescribed to clozapine-treated patients with schizophrenia who had pre-existing metabolic abnormalities. The recruited patients underwent physical and laboratory evaluations at weeks 4, 8, and 12. The outcomes were any changes in metabolic traits. Results Among the 96 clozapine-treated patients with schizophrenia screened for the trial, 55 patients with pre-existing metabolic abnormalities were randomly assigned to placebo (n = 18), metformin dosage at 500 mg/d (n = 18), and metformin dosage at 1000 mg/d (n = 19) groups. The body weight (BW) of patients in the metformin 1000 mg/d group significantly decreased, by a mean of 0.97 kg over the 12 week trial period. Moreover, patients in the metformin at 500 mg/d and 1000 mg/d groups had a significant decrease in body mass index (BMI) after 12 weeks, with the mean decrease being 0.70 and 0.50 kg/m2, respectively. No significant changes were observed in the other metabolic parameters of patients in the three groups. Conclusions Our results demonstrated that a low metformin dosage of either 500 mg/d or 1000 mg/d for 12 weeks slightly reduced the BW and BMI of clozapine-treated patients with pre-existing metabolic abnormalities. A longer period of treatment with a larger sample is warranted to determine the factors that influence the metformin treatment response. Trial Registration ClinicalTrials.gov NCT02751307
Collapse
Affiliation(s)
- Chih-Chiang Chiu
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Mong-Liang Lu
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Ming-Chyi Huang
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Po-Yu Chen
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Graduate Institute of Medical Science, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Yen-Kuang Lin
- Biostatistics Center, Taipei Medical University, Taipei, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chun-Hsin Chen
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
- * E-mail:
| |
Collapse
|
46
|
Adamson P, An FP, Anghel I, Aurisano A, Balantekin AB, Band HR, Barr G, Bishai M, Blake A, Blyth S, Bock GJ, Bogert D, Cao D, Cao GF, Cao J, Cao SV, Carroll TJ, Castromonte CM, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen R, Chen SM, Chen Y, Chen YX, Cheng J, Cheng JH, Cheng YP, Cheng ZK, Cherwinka JJ, Childress S, Chu MC, Chukanov A, Coelho JAB, Corwin L, Cronin-Hennessy D, Cummings JP, de Arcos J, De Rijck S, Deng ZY, Devan AV, Devenish NE, Ding XF, Ding YY, Diwan MV, Dolgareva M, Dove J, Dwyer DA, Edwards WR, Escobar CO, Evans JJ, Falk E, Feldman GJ, Flanagan W, Frohne MV, Gabrielyan M, Gallagher HR, Germani S, Gill R, Gomes RA, Gonchar M, Gong GH, Gong H, Goodman MC, Gouffon P, Graf N, Gran R, Grassi M, Grzelak K, Gu WQ, Guan MY, Guo L, Guo RP, Guo XH, Guo Z, Habig A, Hackenburg RW, Hahn SR, Han R, Hans S, Hartnell J, Hatcher R, He M, Heeger KM, Heng YK, Higuera A, Holin A, Hor YK, Hsiung YB, Hu BZ, Hu T, Hu W, Huang EC, Huang HX, Huang J, Huang XT, Huber P, Huo W, Hussain G, Hylen J, Irwin GM, Isvan Z, Jaffe DE, Jaffke P, James C, Jen KL, Jensen D, Jetter S, Ji XL, Ji XP, Jiao JB, Johnson RA, de Jong JK, Joshi J, Kafka T, Kang L, Kasahara SMS, Kettell SH, Kohn S, Koizumi G, Kordosky M, Kramer M, Kreymer A, Kwan KK, Kwok MW, Kwok T, Lang K, Langford TJ, Lau K, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li DJ, Li F, Li GS, Li QJ, Li S, Li SC, Li WD, Li XN, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Litchfield PJ, Littenberg L, Littlejohn BR, Liu DW, Liu JC, Liu JL, Loh CW, Lu C, Lu HQ, Lu JS, Lucas P, Luk KB, Lv Z, Ma QM, Ma XB, Ma XY, Ma YQ, Malyshkin Y, Mann WA, Marshak ML, Martinez Caicedo DA, Mayer N, McDonald KT, McGivern C, McKeown RD, Medeiros MM, Mehdiyev R, Meier JR, Messier MD, Miller WH, Mishra SR, Mitchell I, Mooney M, Moore CD, Mualem L, Musser J, Nakajima Y, Naples D, Napolitano J, Naumov D, Naumova E, Nelson JK, Newman HB, Ngai HY, Nichol RJ, Ning Z, Nowak JA, O'Connor J, Ochoa-Ricoux JP, Olshevskiy A, Orchanian M, Pahlka RB, Paley J, Pan HR, Park J, Patterson RB, Patton S, Pawloski G, Pec V, Peng JC, Perch A, Pfützner MM, Phan DD, Phan-Budd S, Pinsky L, Plunkett RK, Poonthottathil N, Pun CSJ, Qi FZ, Qi M, Qian X, Qiu X, Radovic A, Raper N, Rebel B, Ren J, Rosenfeld C, Rosero R, Roskovec B, Ruan XC, Rubin HA, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Schreiner P, Sharma R, Moed Sher S, Sousa A, Steiner H, Sun GX, Sun JL, Tagg N, Talaga RL, Tang W, Taychenachev D, Thomas J, Thomson MA, Tian X, Timmons A, Todd J, Tognini SC, Toner R, Torretta D, Treskov K, Tsang KV, Tull CE, Tzanakos G, Urheim J, Vahle P, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang X, Wang YF, Wang Z, Wang ZM, Webb RC, Weber A, Wei HY, Wen LJ, Whisnant K, White C, Whitehead L, Whitehead LH, Wise T, Wojcicki SG, Wong HLH, Wong SCF, Worcester E, Wu CH, Wu Q, Wu WJ, Xia DM, Xia JK, Xing ZZ, Xu JL, Xu JY, Xu Y, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Ye M, Ye Z, Yeh M, Young BL, Yu ZY, Zeng S, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang XT, Zhang YM, Zhang YX, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zhao QW, Zhao YB, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Limits on Active to Sterile Neutrino Oscillations from Disappearance Searches in the MINOS, Daya Bay, and Bugey-3 Experiments. Phys Rev Lett 2016; 117:151801. [PMID: 27768356 DOI: 10.1103/physrevlett.117.151801] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Indexed: 06/06/2023]
Abstract
Searches for a light sterile neutrino have been performed independently by the MINOS and the Daya Bay experiments using the muon (anti)neutrino and electron antineutrino disappearance channels, respectively. In this Letter, results from both experiments are combined with those from the Bugey-3 reactor neutrino experiment to constrain oscillations into light sterile neutrinos. The three experiments are sensitive to complementary regions of parameter space, enabling the combined analysis to probe regions allowed by the Liquid Scintillator Neutrino Detector (LSND) and MiniBooNE experiments in a minimally extended four-neutrino flavor framework. Stringent limits on sin^{2}2θ_{μe} are set over 6 orders of magnitude in the sterile mass-squared splitting Δm_{41}^{2}. The sterile-neutrino mixing phase space allowed by the LSND and MiniBooNE experiments is excluded for Δm_{41}^{2}<0.8 eV^{2} at 95% CL_{s}.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | - I Anghel
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A B Balantekin
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - H R Band
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - G Barr
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Blake
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
- Lancaster University, Lancaster, LA1 4YB, United Kingdom
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
- National United University, Miao-Li
| | - G J Bock
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Bogert
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Cao
- Nanjing University, Nanjing
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - S V Cao
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - C M Castromonte
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - W R Cen
- Institute of High Energy Physics, Beijing
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - L C Chang
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Y Chang
- National United University, Miao-Li
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | | | - R Chen
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
| | - Y X Chen
- North China Electric Power University, Beijing
| | | | - J-H Cheng
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Y P Cheng
- Institute of High Energy Physics, Beijing
| | - Z K Cheng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J J Cherwinka
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | - A Chukanov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J A B Coelho
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - L Corwin
- Indiana University, Bloomington, Indiana 47405, USA
| | | | | | - J de Arcos
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - S De Rijck
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - Z Y Deng
- Institute of High Energy Physics, Beijing
| | - A V Devan
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N E Devenish
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - X F Ding
- Institute of High Energy Physics, Beijing
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Dolgareva
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J Dove
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - C O Escobar
- Universidade Estadual de Campinas, IFGW, CP 6165, 13083-970, Campinas, SP, Brazil
| | - J J Evans
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - E Falk
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - W Flanagan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M V Frohne
- Holy Cross College, Notre Dame, Indiana 46556, USA
| | - M Gabrielyan
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - H R Gallagher
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S Germani
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R Gill
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Gouffon
- Instituto de Física, Universidade de São Paulo, CP 66318, 05315-970, São Paulo, SP, Brazil
| | - N Graf
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - R Gran
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - M Grassi
- Institute of High Energy Physics, Beijing
| | - K Grzelak
- Department of Physics, University of Warsaw, PL-02-093 Warsaw, Poland
| | - W Q Gu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - M Y Guan
- Institute of High Energy Physics, Beijing
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - R P Guo
- Institute of High Energy Physics, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | - Z Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - A Habig
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - R W Hackenburg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Han
- North China Electric Power University, Beijing
| | - S Hans
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - A Holin
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - Y K Hor
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - W Hu
- Institute of High Energy Physics, Beijing
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | | | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - W Huo
- University of Science and Technology of China, Hefei
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Hylen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G M Irwin
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - Z Isvan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Jaffke
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - C James
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - D Jensen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Jetter
- Institute of High Energy Physics, Beijing
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | - X P Ji
- Department of Engineering Physics, Tsinghua University, Beijing
- School of Physics, Nankai University, Tianjin
| | | | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J K de Jong
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - J Joshi
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Kafka
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S M S Kasahara
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Kohn
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G Koizumi
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Kordosky
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong
| | - T Kwok
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Langford
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - J H C Lee
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C Li
- Shandong University, Jinan
| | - D J Li
- University of Science and Technology of China, Hefei
| | - F Li
- Institute of High Energy Physics, Beijing
| | - G S Li
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - S Li
- Dongguan University of Technology, Dongguan
| | - S C Li
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Lin
- Dongguan University of Technology, Dongguan
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - Y-C Lin
- Department of Physics, National Taiwan University, Taipei
| | - J J Ling
- Brookhaven National Laboratory, Upton, New York 11973, USA
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - P J Litchfield
- University of Minnesota, Minneapolis, Minnesota 55455, USA
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - D W Liu
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | - J L Liu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | | | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544, USA
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - J S Lu
- Institute of High Energy Physics, Beijing
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - Z Lv
- Xi'an Jiaotong University, Xi'an
| | - Q M Ma
- Institute of High Energy Physics, Beijing
| | - X B Ma
- North China Electric Power University, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - Y Malyshkin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - W A Mann
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - D A Martinez Caicedo
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - N Mayer
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544, USA
| | - C McGivern
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - R D McKeown
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - M M Medeiros
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J R Meier
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - W H Miller
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M Mooney
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C D Moore
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Mualem
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - J Musser
- Indiana University, Bloomington, Indiana 47405, USA
| | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - D Naples
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - H B Newman
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R J Nichol
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - Z Ning
- Institute of High Energy Physics, Beijing
| | - J A Nowak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J O'Connor
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J P Ochoa-Ricoux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - M Orchanian
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R B Pahlka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Paley
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - R B Patterson
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G Pawloski
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - A Perch
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M M Pfützner
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - S Phan-Budd
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Poonthottathil
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N Raper
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - H A Rubin
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - P Sail
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M C Sanchez
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Schneps
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - A Schreckenberger
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Schreiner
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R Sharma
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Moed Sher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G X Sun
- Institute of High Energy Physics, Beijing
| | - J L Sun
- China General Nuclear Power Group
| | - N Tagg
- Otterbein University, Westerville, Ohio 43081, USA
| | - R L Talaga
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - W Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Taychenachev
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J Thomas
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M A Thomson
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
| | - X Tian
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Timmons
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - J Todd
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Treskov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G Tzanakos
- Department of Physics, University of Athens, GR-15771 Athens, Greece
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N Viaux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - C H Wang
- National United University, Miao-Li
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - R C Webb
- Physics Department, Texas A&M University, College Station, Texas 77843, USA
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - H Y Wei
- Department of Engineering Physics, Tsinghua University, Beijing
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | - K Whisnant
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - C White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L H Whitehead
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - T Wise
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S C F Wong
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C-H Wu
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Q Wu
- Shandong University, Jinan
| | - W J Wu
- Institute of High Energy Physics, Beijing
| | - D M Xia
- Chongqing University, Chongqing
| | - J K Xia
- Institute of High Energy Physics, Beijing
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - J Y Xu
- Chinese University of Hong Kong, Hong Kong
| | - Y Xu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - H Yang
- Nanjing University, Nanjing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | | | - M Ye
- Institute of High Energy Physics, Beijing
| | - Z Ye
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B L Young
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | - S Zeng
- Institute of High Energy Physics, Beijing
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | | | - X T Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | | | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - Q W Zhao
- Institute of High Energy Physics, Beijing
| | - Y B Zhao
- Institute of High Energy Physics, Beijing
| | - W L Zhong
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - N Zhou
- University of Science and Technology of China, Hefei
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
47
|
An FP, Balantekin AB, Band HR, Bishai M, Blyth S, Cao D, Cao GF, Cao J, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen SM, Chen YX, Chen Y, Cheng JH, Cheng J, Cheng YP, Cheng ZK, Cherwinka JJ, Chu MC, Chukanov A, Cummings JP, de Arcos J, Deng ZY, Ding XF, Ding YY, Diwan MV, Dolgareva M, Dove J, Dwyer DA, Edwards WR, Gill R, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guan MY, Guo L, Guo RP, Guo XH, Guo Z, Hackenburg RW, Han R, Hans S, He M, Heeger KM, Heng YK, Higuera A, Hor YK, Hsiung YB, Hu BZ, Hu T, Hu W, Huang EC, Huang HX, Huang XT, Huber P, Huo W, Hussain G, Jaffe DE, Jaffke P, Jen KL, Jetter S, Ji XP, Ji XL, Jiao JB, Johnson RA, Joshi J, Kang L, Kettell SH, Kohn S, Kramer M, Kwan KK, Kwok MW, Kwok T, Langford TJ, Lau K, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li DJ, Li F, Li GS, Li QJ, Li S, Li SC, Li WD, Li XN, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu DW, Liu JL, Liu JC, Loh CW, Lu C, Lu HQ, Lu JS, Luk KB, Lv Z, Ma QM, Ma XY, Ma XB, Ma YQ, Malyshkin Y, Martinez Caicedo DA, McDonald KT, McKeown RD, Mitchell I, Mooney M, Nakajima Y, Napolitano J, Naumov D, Naumova E, Ngai HY, Ning Z, Ochoa-Ricoux JP, Olshevskiy A, Pan HR, Park J, Patton S, Pec V, Peng JC, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Raper N, Ren J, Rosero R, Roskovec B, Ruan XC, Steiner H, Sun GX, Sun JL, Tang W, Taychenachev D, Treskov K, Tsang KV, Tull CE, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Wei HY, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu CH, Wu Q, Wu WJ, Xia DM, Xia JK, Xing ZZ, Xu JY, Xu JL, Xu Y, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Ye M, Ye Z, Yeh M, Young BL, Yu ZY, Zeng S, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang XT, Zhang YM, Zhang YX, Zhang YM, Zhang ZJ, Zhang ZY, Zhang ZP, Zhao J, Zhao QW, Zhao YB, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Improved Search for a Light Sterile Neutrino with the Full Configuration of the Daya Bay Experiment. Phys Rev Lett 2016; 117:151802. [PMID: 27768341 DOI: 10.1103/physrevlett.117.151802] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Indexed: 06/06/2023]
Abstract
This Letter reports an improved search for light sterile neutrino mixing in the electron antineutrino disappearance channel with the full configuration of the Daya Bay Reactor Neutrino Experiment. With an additional 404 days of data collected in eight antineutrino detectors, this search benefits from 3.6 times the statistics available to the previous publication, as well as from improvements in energy calibration and background reduction. A relative comparison of the rate and energy spectrum of reactor antineutrinos in the three experimental halls yields no evidence of sterile neutrino mixing in the 2×10^{-4}≲|Δm_{41}^{2}|≲0.3 eV^{2} mass range. The resulting limits on sin^{2}2θ_{14} are improved by approx imately a factor of 2 over previous results and constitute the most stringent constraints to date in the |Δm_{41}^{2}|≲0.2 eV^{2} region.
Collapse
Affiliation(s)
- F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | | | - H R Band
- Department of Physics, Yale University, New Haven, Connecticut USA
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York USA
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
- National United University, Miao-Li
| | - D Cao
- Nanjing University, Nanjing
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - W R Cen
- Institute of High Energy Physics, Beijing
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - L C Chang
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Y Chang
- National United University, Miao-Li
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | | | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y X Chen
- North China Electric Power University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
| | - J-H Cheng
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | | | - Y P Cheng
- Institute of High Energy Physics, Beijing
| | - Z K Cheng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | | | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | - A Chukanov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | | | - J de Arcos
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois USA
| | - Z Y Deng
- Institute of High Energy Physics, Beijing
| | - X F Ding
- Institute of High Energy Physics, Beijing
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York USA
| | - M Dolgareva
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J Dove
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois USA
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - R Gill
- Brookhaven National Laboratory, Upton, New York USA
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - M Grassi
- Institute of High Energy Physics, Beijing
| | - W Q Gu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - M Y Guan
- Institute of High Energy Physics, Beijing
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - R P Guo
- Institute of High Energy Physics, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | - Z Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | | | - R Han
- North China Electric Power University, Beijing
| | - S Hans
- Brookhaven National Laboratory, Upton, New York USA
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Department of Physics, Yale University, New Haven, Connecticut USA
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas USA
| | - Y K Hor
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia USA
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - W Hu
- Institute of High Energy Physics, Beijing
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois USA
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | | | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia USA
| | - W Huo
- University of Science and Technology of China, Hefei
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York USA
| | - P Jaffke
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia USA
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Jetter
- Institute of High Energy Physics, Beijing
| | - X P Ji
- Department of Engineering Physics, Tsinghua University, Beijing
- School of Physics, Nankai University, Tianjin
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | | | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio USA
| | - J Joshi
- Brookhaven National Laboratory, Upton, New York USA
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York USA
| | - S Kohn
- Department of Physics, University of California, Berkeley, California USA
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California USA
- Department of Physics, University of California, Berkeley, California USA
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong
| | - T Kwok
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - T J Langford
- Department of Physics, Yale University, New Haven, Connecticut USA
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas USA
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - J H C Lee
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C Li
- Shandong University, Jinan
| | - D J Li
- University of Science and Technology of China, Hefei
| | - F Li
- Institute of High Energy Physics, Beijing
| | - G S Li
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - S Li
- Dongguan University of Technology, Dongguan
| | - S C Li
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia USA
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Lin
- Dongguan University of Technology, Dongguan
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas USA
| | - Y-C Lin
- Department of Physics, National Taiwan University, Taipei
| | - J J Ling
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia USA
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York USA
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois USA
| | - D W Liu
- Department of Physics, University of Houston, Houston, Texas USA
| | - J L Liu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | | | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey USA
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - J S Lu
- Institute of High Energy Physics, Beijing
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California USA
- Department of Physics, University of California, Berkeley, California USA
| | - Z Lv
- Xi'an Jiaotong University, Xi'an
| | - Q M Ma
- Institute of High Energy Physics, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - X B Ma
- North China Electric Power University, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - Y Malyshkin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | | | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey USA
| | - R D McKeown
- California Institute of Technology, Pasadena, California USA
- College of William and Mary, Williamsburg, Virginia USA
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas USA
| | - M Mooney
- Brookhaven National Laboratory, Upton, New York USA
| | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania USA
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - Z Ning
- Institute of High Energy Physics, Beijing
| | - J P Ochoa-Ricoux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia USA
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois USA
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas USA
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York USA
| | - N Raper
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York USA
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York USA
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California USA
- Department of Physics, University of California, Berkeley, California USA
| | - G X Sun
- Institute of High Energy Physics, Beijing
| | - J L Sun
- China General Nuclear Power Group, Shenzhen
| | - W Tang
- Brookhaven National Laboratory, Upton, New York USA
| | - D Taychenachev
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K Treskov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California USA
| | - N Viaux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - B Viren
- Brookhaven National Laboratory, Upton, New York USA
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - C H Wang
- National United University, Miao-Li
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- College of William and Mary, Williamsburg, Virginia USA
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - H Y Wei
- Department of Engineering Physics, Tsinghua University, Beijing
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | | | - C G White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois USA
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas USA
| | - T Wise
- University of Wisconsin, Madison, Wisconsin USA
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California USA
- Department of Physics, University of California, Berkeley, California USA
| | - S C F Wong
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York USA
| | - C-H Wu
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Q Wu
- Shandong University, Jinan
| | - W J Wu
- Institute of High Energy Physics, Beijing
| | - D M Xia
- Chongqing University, Chongqing
| | - J K Xia
- Institute of High Energy Physics, Beijing
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J Y Xu
- Chinese University of Hong Kong, Hong Kong
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - Y Xu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - H Yang
- Nanjing University, Nanjing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | | | - M Ye
- Institute of High Energy Physics, Beijing
| | - Z Ye
- Department of Physics, University of Houston, Houston, Texas USA
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York USA
| | - B L Young
- Iowa State University, Ames, Iowa USA
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | - S Zeng
- Institute of High Energy Physics, Beijing
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York USA
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | | | - X T Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y X Zhang
- China General Nuclear Power Group, Shenzhen
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - Q W Zhao
- Institute of High Energy Physics, Beijing
| | - Y B Zhao
- Institute of High Energy Physics, Beijing
| | - W L Zhong
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - N Zhou
- University of Science and Technology of China, Hefei
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
48
|
Huang MC, Yang SY, Lin SK, Chen KY, Chen YY, Kuo CJ, Hung YN. Risk of Cardiovascular Diseases and Stroke Events in Methamphetamine Users: A 10-Year Follow-Up Study. J Clin Psychiatry 2016; 77:1396-1403. [PMID: 27574836 DOI: 10.4088/jcp.15m09872] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Accepted: 11/24/2015] [Indexed: 10/21/2022]
Abstract
OBJECTIVE Long-term follow-up data regarding the association between methamphetamine use and cardiovascular and cerebrovascular complications are scarce. We investigated the risk of complications in methamphetamine users over a decade. METHODS A total of 1,315 inpatients treated for methamphetamine use were recruited from the Psychiatric Inpatient Medical Claims database in Taiwan between January 1, 1997, and December 31, 2000, and matched with a population proxy comparison group at a ratio of 1:4 through propensity score matching. All patients were monitored for any incident complication until December 31, 2010. Cox proportional hazards model was used to estimate the risk of ICD-9-CM cardiovascular diseases and stroke events. RESULTS The patients were mostly male, and approximately half were younger than 30 years. The methamphetamine cohort had higher incidences of cardiovascular diseases and stroke events than the comparison cohort (87.5/10,000 vs 55.3/10,000 person-years, P < .001) and was significantly associated with an increased risk of the complications (hazard ratio [HR] = 1.55, P < .001), particularly arrhythmia (HR = 1.92, P = .014) and hemorrhagic stroke (HR = 2.09, P = .001). The risk of cardiovascular sequelae was more significant in younger patients (< 30 y) (HR = 2.22, P = .001), whereas the risk of stroke events was higher among the older patients (≥ 30 y) (HR = 1.86, P = .001). CONCLUSIONS Methamphetamine use is significantly associated with a risk of subsequent cardiovascular and cerebrovascular complications. Age appears to be an effect modifier for the risk estimation.
Collapse
Affiliation(s)
- Ming-Chyi Huang
- Department of Psychiatry, Taipei City Hospital, Taiwan.,Department of Psychiatry, School of Medicine, College of Nursing, Taipei Medical University, Taiwan
| | - Shu-Yu Yang
- Department of Pharmacy, Taipei City Psychiatric Center, Taipei City Hospital, Taiwan
| | - Shih-Ku Lin
- Department of Psychiatry, Taipei City Hospital, Taiwan.,Department of Psychiatry, School of Medicine, College of Nursing, Taipei Medical University, Taiwan
| | - Kuan-Yu Chen
- Department of Psychiatry, Taipei City Hospital, Taiwan.,Department of Psychiatry, National Yang-Ming University, Taipei, Taiwan
| | - Ying-Yeh Chen
- Department of Psychiatry, Taipei City Hospital, Taiwan.,Institute of Public Health, Department of Public Health, National Yang-Ming University, Taipei, Taiwan
| | - Chian-Jue Kuo
- Department of Psychiatry, Taipei City Hospital, Taiwan.,Department of Psychiatry, School of Medicine, College of Nursing, Taipei Medical University, Taiwan
| | - Yen-Ni Hung
- School of Gerontology Health Management and Master Program in Long-Term Care, College of Nursing, Taipei Medical University, No 250, Wu-Hsing St, Taipei 11031, Taiwan. .,School of Gerontology Health Management and Master Program in Long-Term Care, College of Nursing, Taipei Medical University, Taiwan
| |
Collapse
|
49
|
Kao CF, Chen HW, Chen HC, Yang JH, Huang MC, Chiu YH, Lin SK, Lee YC, Liu CM, Chuang LC, Chen CH, Wu JY, Lu RB, Kuo PH. Identification of Susceptible Loci and Enriched Pathways for Bipolar II Disorder Using Genome-Wide Association Studies. Int J Neuropsychopharmacol 2016; 19:pyw064. [PMID: 27450446 PMCID: PMC5203756 DOI: 10.1093/ijnp/pyw064] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Accepted: 07/11/2016] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND This study aimed to identify susceptible loci and enriched pathways for bipolar disorder subtype II. METHODS We conducted a genome-wide association scan in discovery samples with 189 bipolar disorder subtype II patients and 1773 controls, and replication samples with 283 bipolar disorder subtype II patients and 500 controls in a Taiwanese Han population using Affymetrix Axiom Genome-Wide CHB1 Array. We performed single-marker and gene-based association analyses, as well as calculated polygeneic risk scores for bipolar disorder subtype II. Pathway enrichment analyses were employed to reveal significant biological pathways. RESULTS Seven markers were found to be associated with bipolar disorder subtype II in meta-analysis combining both discovery and replication samples (P<5.0×10-6), including markers in or close to MYO16, HSP90AB3P, noncoding gene LOC100507632, and markers in chromosomes 4 and 10. A novel locus, ETF1, was associated with bipolar disorder subtype II (P<6.0×10-3) in gene-based association tests. Results of risk evaluation demonstrated that higher genetic risk scores were able to distinguish bipolar disorder subtype II patients from healthy controls in both discovery (P=3.9×10-4~1.0×10-3) and replication samples (2.8×10-4~1.7×10-3). Genetic variance explained by chip markers for bipolar disorder subtype II was substantial in the discovery (55.1%) and replication (60.5%) samples. Moreover, pathways related to neurodevelopmental function, signal transduction, neuronal system, and cell adhesion molecules were significantly associated with bipolar disorder subtype II. CONCLUSION We reported novel susceptible loci for pure bipolar subtype II disorder that is less addressed in the literature. Future studies are needed to confirm the roles of these loci for bipolar disorder subtype II.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Ru-Band Lu
- Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan (Dr Kao, Mr Lee, and Dr Kuo); Department of Agronomy, College of Agriculture & Natural Resources, National Chung Hsing University, Taichung, Taiwan (Dr Kao); National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (Mrs Chen, Dr Yang, Dr Chen, and Dr Wu); Department of Psychiatry & Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan (Dr Chen); Department of Nursing, Cardinal Tien Junior College of Healthcare & Management, Yilan, Taiwan (Dr Chuang); Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan (Drs Huang, Chiu, and Lin); Department of Psychiatry, Taipei City Psychiatric Center, Taipei, Taiwan (Dr Huang); Department of Psychiatry, Wan Fang Medical Center, Taipei, Taiwan (Dr Chiu); Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan (Dr Lin); Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan (Dr Liu); Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan (Dr Liu); Department of Psychiatry, National Cheng Kung University and Hospital, Tainan, Taiwan (Dr Lu); Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei, Taiwan (Dr Kuo).
| | - Po-Hsiu Kuo
- Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan (Dr Kao, Mr Lee, and Dr Kuo); Department of Agronomy, College of Agriculture & Natural Resources, National Chung Hsing University, Taichung, Taiwan (Dr Kao); National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (Mrs Chen, Dr Yang, Dr Chen, and Dr Wu); Department of Psychiatry & Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan (Dr Chen); Department of Nursing, Cardinal Tien Junior College of Healthcare & Management, Yilan, Taiwan (Dr Chuang); Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan (Drs Huang, Chiu, and Lin); Department of Psychiatry, Taipei City Psychiatric Center, Taipei, Taiwan (Dr Huang); Department of Psychiatry, Wan Fang Medical Center, Taipei, Taiwan (Dr Chiu); Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan (Dr Lin); Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan (Dr Liu); Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan (Dr Liu); Department of Psychiatry, National Cheng Kung University and Hospital, Tainan, Taiwan (Dr Lu); Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei, Taiwan (Dr Kuo).
| |
Collapse
|
50
|
An FP, Balantekin AB, Band HR, Bishai M, Blyth S, Butorov I, Cao D, Cao GF, Cao J, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen SM, Chen YX, Chen Y, Cheng JH, Cheng J, Cheng YP, Cherwinka JJ, Chu MC, Cummings JP, de Arcos J, Deng ZY, Ding XF, Ding YY, Diwan MV, Dove J, Draeger E, Dwyer DA, Edwards WR, Ely SR, Gill R, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guan MY, Guo L, Guo XH, Hackenburg RW, Han R, Hans S, He M, Heeger KM, Heng YK, Higuera A, Hor YK, Hsiung YB, Hu BZ, Hu LM, Hu LJ, Hu T, Hu W, Huang EC, Huang HX, Huang XT, Huber P, Hussain G, Jaffe DE, Jaffke P, Jen KL, Jetter S, Ji XP, Ji XL, Jiao JB, Johnson RA, Kang L, Kettell SH, Kohn S, Kramer M, Kwan KK, Kwok MW, Kwok T, Langford TJ, Lau K, Lebanowski L, Lee J, Lei RT, Leitner R, Leung KY, Leung JKC, Lewis CA, Li DJ, Li F, Li GS, Li QJ, Li SC, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin PY, Lin SK, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu DW, Liu H, Liu JL, Liu JC, Liu SS, Lu C, Lu HQ, Lu JS, Luk KB, Ma QM, Ma XY, Ma XB, Ma YQ, Martinez Caicedo DA, McDonald KT, McKeown RD, Meng Y, Mitchell I, Monari Kebwaro J, Nakajima Y, Napolitano J, Naumov D, Naumova E, Ngai HY, Ning Z, Ochoa-Ricoux JP, Olshevski A, Pan HR, Park J, Patton S, Pec V, Peng JC, Piilonen LE, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Raper N, Ren B, Ren J, Rosero R, Roskovec B, Ruan XC, Shao BB, Steiner H, Sun GX, Sun JL, Tang W, Taychenachev D, Tsang KV, Tull CE, Tung YC, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang WW, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Wei HY, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu Q, Xia DM, Xia JK, Xia X, Xing ZZ, Xu JY, Xu JL, Xu J, Xu Y, Xue T, Yan J, Yang CG, Yang L, Yang MS, Yang MT, Ye M, Yeh M, Young BL, Yu GY, Yu ZY, Zang SL, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang YM, Zhang YX, Zhang YM, Zhang ZJ, Zhang ZY, Zhang ZP, Zhao J, Zhao QW, Zhao YF, Zhao YB, Zheng L, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Measurement of the Reactor Antineutrino Flux and Spectrum at Daya Bay. Phys Rev Lett 2016; 116:061801. [PMID: 26918980 DOI: 10.1103/physrevlett.116.061801] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Indexed: 06/05/2023]
Abstract
This Letter reports a measurement of the flux and energy spectrum of electron antineutrinos from six 2.9 GWth nuclear reactors with six detectors deployed in two near (effective baselines 512 and 561 m) and one far (1579 m) underground experimental halls in the Daya Bay experiment. Using 217 days of data, 296 721 and 41 589 inverse β decay (IBD) candidates were detected in the near and far halls, respectively. The measured IBD yield is (1.55±0.04) ×10(-18) cm(2) GW(-1) day(-1) or (5.92±0.14) ×10(-43) cm(2) fission(-1). This flux measurement is consistent with previous short-baseline reactor antineutrino experiments and is 0.946±0.022 (0.991±0.023) relative to the flux predicted with the Huber-Mueller (ILL-Vogel) fissile antineutrino model. The measured IBD positron energy spectrum deviates from both spectral predictions by more than 2σ over the full energy range with a local significance of up to ∼4σ between 4-6 MeV. A reactor antineutrino spectrum of IBD reactions is extracted from the measured positron energy spectrum for model-independent predictions.
Collapse
Affiliation(s)
- F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai, China
| | | | - H R Band
- Department of Physics, Yale University, New Haven, Connecticut, USA
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York, USA
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei, Taiwan
- National United University, Miao-Li, Taiwan
| | - I Butorov
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - D Cao
- Nanjing University, Nanjing, China
| | - G F Cao
- Institute of High Energy Physics, Beijing, China
| | - J Cao
- Institute of High Energy Physics, Beijing, China
| | - W R Cen
- Institute of High Energy Physics, Beijing, China
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong, China
| | - J F Chang
- Institute of High Energy Physics, Beijing, China
| | - L C Chang
- Institute of Physics, National Chiao-Tung University, Hsinchu, Taiwan
| | - Y Chang
- National United University, Miao-Li, Taiwan
| | - H S Chen
- Institute of High Energy Physics, Beijing, China
| | - Q Y Chen
- Shandong University, Jinan, China
| | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - Y X Chen
- North China Electric Power University, Beijing, China
| | - Y Chen
- Shenzhen University, Shenzhen, China
| | - J H Cheng
- Institute of Physics, National Chiao-Tung University, Hsinchu, Taiwan
| | - J Cheng
- Shandong University, Jinan, China
| | - Y P Cheng
- Institute of High Energy Physics, Beijing, China
| | | | - M C Chu
- Chinese University of Hong Kong, Hong Kong, China
| | | | - J de Arcos
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
| | - Z Y Deng
- Institute of High Energy Physics, Beijing, China
| | - X F Ding
- Institute of High Energy Physics, Beijing, China
| | - Y Y Ding
- Institute of High Energy Physics, Beijing, China
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York, USA
| | - J Dove
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - E Draeger
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - S R Ely
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - R Gill
- Brookhaven National Laboratory, Upton, New York, USA
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - M Grassi
- Institute of High Energy Physics, Beijing, China
| | - W Q Gu
- Shanghai Jiao Tong University, Shanghai, China
| | - M Y Guan
- Institute of High Energy Physics, Beijing, China
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - X H Guo
- Beijing Normal University, Beijing, China
| | | | - R Han
- North China Electric Power University, Beijing, China
| | - S Hans
- Brookhaven National Laboratory, Upton, New York, USA
| | - M He
- Institute of High Energy Physics, Beijing, China
| | - K M Heeger
- Department of Physics, Yale University, New Haven, Connecticut, USA
| | - Y K Heng
- Institute of High Energy Physics, Beijing, China
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas, USA
| | - Y K Hor
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei, Taiwan
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei, Taiwan
| | - L M Hu
- Brookhaven National Laboratory, Upton, New York, USA
| | - L J Hu
- Beijing Normal University, Beijing, China
| | - T Hu
- Institute of High Energy Physics, Beijing, China
| | - W Hu
- Institute of High Energy Physics, Beijing, China
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - H X Huang
- China Institute of Atomic Energy, Beijing, China
| | | | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York, USA
| | - P Jaffke
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu, Taiwan
| | - S Jetter
- Institute of High Energy Physics, Beijing, China
| | - X P Ji
- Department of Engineering Physics, Tsinghua University, Beijing, China
- School of Physics, Nankai University, Tianjin, China
| | - X L Ji
- Institute of High Energy Physics, Beijing, China
| | - J B Jiao
- Shandong University, Jinan, China
| | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio, USA
| | - L Kang
- Dongguan University of Technology, Dongguan, China
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York, USA
| | - S Kohn
- Department of Physics, University of California, Berkeley, California, USA
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
- Department of Physics, University of California, Berkeley, California, USA
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong, China
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong, China
| | - T Kwok
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - T J Langford
- Department of Physics, Yale University, New Haven, Connecticut, USA
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas, USA
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - R T Lei
- Dongguan University of Technology, Dongguan, China
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - K Y Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - C A Lewis
- University of Wisconsin, Madison, Wisconsin, USA
| | - D J Li
- University of Science and Technology of China, Hefei, China
| | - F Li
- Institute of High Energy Physics, Beijing, China
| | - G S Li
- Shanghai Jiao Tong University, Shanghai, China
| | - Q J Li
- Institute of High Energy Physics, Beijing, China
| | - S C Li
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - W D Li
- Institute of High Energy Physics, Beijing, China
| | - X N Li
- Institute of High Energy Physics, Beijing, China
| | - X Q Li
- School of Physics, Nankai University, Tianjin, China
| | - Y F Li
- Institute of High Energy Physics, Beijing, China
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou, China
| | - H Liang
- University of Science and Technology of China, Hefei, China
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu, Taiwan
| | - P Y Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu, Taiwan
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas, USA
| | - J J Ling
- Brookhaven National Laboratory, Upton, New York, USA
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
- Sun Yat-Sen (Zhongshan) University, Guangzhou, China
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York, USA
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
- Department of Physics, University of Cincinnati, Cincinnati, Ohio, USA
| | - D W Liu
- Department of Physics, University of Houston, Houston, Texas, USA
| | - H Liu
- Department of Physics, University of Houston, Houston, Texas, USA
| | - J L Liu
- Shanghai Jiao Tong University, Shanghai, China
| | - J C Liu
- Institute of High Energy Physics, Beijing, China
| | - S S Liu
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey, USA
| | - H Q Lu
- Institute of High Energy Physics, Beijing, China
| | - J S Lu
- Institute of High Energy Physics, Beijing, China
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
- Department of Physics, University of California, Berkeley, California, USA
| | - Q M Ma
- Institute of High Energy Physics, Beijing, China
| | - X Y Ma
- Institute of High Energy Physics, Beijing, China
| | - X B Ma
- North China Electric Power University, Beijing, China
| | - Y Q Ma
- Institute of High Energy Physics, Beijing, China
| | | | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey, USA
| | - R D McKeown
- California Institute of Technology, Pasadena, California, USA
- College of William and Mary, Williamsburg, Virginia, USA
| | - Y Meng
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas, USA
| | | | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Z Ning
- Institute of High Energy Physics, Beijing, China
| | - J P Ochoa-Ricoux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - A Olshevski
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei, Taiwan
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - L E Piilonen
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas, USA
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - F Z Qi
- Institute of High Energy Physics, Beijing, China
| | - M Qi
- Nanjing University, Nanjing, China
| | - X Qian
- Brookhaven National Laboratory, Upton, New York, USA
| | - N Raper
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York, USA
| | - B Ren
- Dongguan University of Technology, Dongguan, China
| | - J Ren
- China Institute of Atomic Energy, Beijing, China
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York, USA
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - X C Ruan
- China Institute of Atomic Energy, Beijing, China
| | - B B Shao
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
- Department of Physics, University of California, Berkeley, California, USA
| | - G X Sun
- Institute of High Energy Physics, Beijing, China
| | - J L Sun
- China General Nuclear Power Group, China
| | - W Tang
- Brookhaven National Laboratory, Upton, New York, USA
| | - D Taychenachev
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - Y C Tung
- Department of Physics, National Taiwan University, Taipei, Taiwan
| | - N Viaux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - B Viren
- Brookhaven National Laboratory, Upton, New York, USA
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - C H Wang
- National United University, Miao-Li, Taiwan
| | - M Wang
- Shandong University, Jinan, China
| | - N Y Wang
- Beijing Normal University, Beijing, China
| | - R G Wang
- Institute of High Energy Physics, Beijing, China
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou, China
- College of William and Mary, Williamsburg, Virginia, USA
| | - W W Wang
- Nanjing University, Nanjing, China
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha, China
| | - Y F Wang
- Institute of High Energy Physics, Beijing, China
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - Z Wang
- Institute of High Energy Physics, Beijing, China
| | - Z M Wang
- Institute of High Energy Physics, Beijing, China
| | - H Y Wei
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - L J Wen
- Institute of High Energy Physics, Beijing, China
| | | | - C G White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas, USA
| | - T Wise
- University of Wisconsin, Madison, Wisconsin, USA
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
- Department of Physics, University of California, Berkeley, California, USA
| | - S C F Wong
- Chinese University of Hong Kong, Hong Kong, China
- Sun Yat-Sen (Zhongshan) University, Guangzhou, China
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York, USA
| | - Q Wu
- Shandong University, Jinan, China
| | - D M Xia
- Institute of High Energy Physics, Beijing, China
- Chongqing University, Chongqing, China
| | - J K Xia
- Institute of High Energy Physics, Beijing, China
| | - X Xia
- Shandong University, Jinan, China
| | - Z Z Xing
- Institute of High Energy Physics, Beijing, China
| | - J Y Xu
- Chinese University of Hong Kong, Hong Kong, China
| | - J L Xu
- Institute of High Energy Physics, Beijing, China
| | - J Xu
- Beijing Normal University, Beijing, China
| | - Y Xu
- School of Physics, Nankai University, Tianjin, China
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - J Yan
- Xi'an Jiaotong University, Xi'an, China
| | - C G Yang
- Institute of High Energy Physics, Beijing, China
| | - L Yang
- Dongguan University of Technology, Dongguan, China
| | - M S Yang
- Institute of High Energy Physics, Beijing, China
| | - M T Yang
- Shandong University, Jinan, China
| | - M Ye
- Institute of High Energy Physics, Beijing, China
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York, USA
| | - B L Young
- Iowa State University, Ames, Iowa, USA
| | - G Y Yu
- Nanjing University, Nanjing, China
| | - Z Y Yu
- Institute of High Energy Physics, Beijing, China
| | - S L Zang
- Nanjing University, Nanjing, China
| | - L Zhan
- Institute of High Energy Physics, Beijing, China
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York, USA
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou, China
| | - J W Zhang
- Institute of High Energy Physics, Beijing, China
| | - Q M Zhang
- Xi'an Jiaotong University, Xi'an, China
| | - Y M Zhang
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - Y X Zhang
- China General Nuclear Power Group, China
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou, China
| | - Z J Zhang
- Dongguan University of Technology, Dongguan, China
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing, China
| | - Z P Zhang
- University of Science and Technology of China, Hefei, China
| | - J Zhao
- Institute of High Energy Physics, Beijing, China
| | - Q W Zhao
- Institute of High Energy Physics, Beijing, China
| | - Y F Zhao
- North China Electric Power University, Beijing, China
| | - Y B Zhao
- Institute of High Energy Physics, Beijing, China
| | - L Zheng
- University of Science and Technology of China, Hefei, China
| | - W L Zhong
- Institute of High Energy Physics, Beijing, China
| | - L Zhou
- Institute of High Energy Physics, Beijing, China
| | - N Zhou
- University of Science and Technology of China, Hefei, China
| | - H L Zhuang
- Institute of High Energy Physics, Beijing, China
| | - J H Zou
- Institute of High Energy Physics, Beijing, China
| |
Collapse
|